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Abstract 
 
Early human fetuses have the ability to heal wounds by completely 
regenerating tissues, leaving no evidence of scarring. However in the adult 
scarring is the inevitable endpoint of the wound healing process. Sometimes 
these scars can be pathological in nature causing both functional and 
aesthetic problems to those affected. Every year millions of people around the 
globe acquire problematic or pathological scars either whilst undergoing 
surgery or from traumatic injuries and at present there remain a severely 
limited number of pharmacological treatment options to offer these patients. 
Importantly currently there exists no treatment that can either eliminate or 
reliably reduce acquired scars.  
Not only is the treatment of acquired scars problematic but also the clinical 
assessment of scars is largely subjective in nature and frequently relies on 
assessment scales that show large amounts of inter-rater variation and lack 
quantification. Especially subjective is the measurement of scar colour, which 
can be markedly different from the surrounding skin and cause significant 
distress to the patient.  Without an objective assessment framework clinicians 
cannot reliably examine scars nor gauge responses to any treatment. 
The aim of this thesis is thus two-fold. Firstly a new anti-scarring treatment in 
the form of insulin will be tested in a randomised, double blind, intra-patient, 
placebo controlled trial where patients undergoing elective bilateral breast 
surgery will have low-dose insulin injected subcutaneously to one breast and 
placebo to the other at the time of surgery. Patients will be followed up for 12 
months and their scars compared to examine the therapeutic effect of insulin 
upon scars. Secondly the thesis aims to test the validity of new methods of 
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assessing the scar colour of a subset of patients within the insulin trial using 
previously untested photographic devices and software. These devices are 
hoped to add much needed quantification to scar assessment.   
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STUDY AIMS & BACKGROUND 
 
This thesis furthers previous work undertaken at the RAFT Institute of Plastic 
Surgery by Mackie and Baker researching the antiscarring properties of 
insulin through the conduction of a randomised double blind, intra-patient, 
placebo-controlled trial 1,2. This thesis also aims to develop and investigate 
the feasibility of new scar assessment systems. 
 
Scarring is a major clinical problem that occurs following dermal injury. Every 
year a 100 million people in the Western world acquire new scars, some of 
which cause significant problems to those afflicted 3. Despite the scale of the 
problem there are currently no effective treatments for reducing or preventing 
scarring available on the commercial market 3. However we now have a 
considerable amount of (unpublished) laboratory data to support a novel use for 
insulin in the control of scarring. When dermal fibroblasts derived from both 
mouse and human skin are cultured in the presence of insulin, there is a 
substantial reduction in the differentiation of the activated fibroblasts, or 
myofibroblasts, that are responsible for the formation of scar tissue, when 
compared with cultures of such cells in the absence of insulin 1,2 . 
 
Insulin treatment appears to be equally effective upon fibroblasts derived from 
physiologically normal scar tissue and the excessive pathological scar tissue of 
keloid and hypertrophic scars 2. Extension of this work into an animal (mouse) 
model of wound healing has shown that a single injection of a low dose (0.15 
International Units) of a commercially available clinical formulation of insulin 
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(Insulatard®) within 24 hours of wounding dramatically reduces the presence of 
the scar-tissue-forming cells in the later stages (post 14 days) of healing 1,2. 
 
A pilot clinical study to evaluate the efficacy of insulin as an anti-scarring therapy 
on humans was conducted from 2005 to 2007 1. This study examined the effect 
of insulin on scar formation in patients undergoing bilateral breast reduction 
surgery. This pilot study was a randomised double blind, intra-patient, placebo-
controlled trial performed by randomised application of either insulin (0.3 
International Units total) or vehicle-only control to the lateral-most 3cm length of 
the wound under each breast in 15 patients (30 wounds total). The patients 
were followed up for 3 months post-operatively and their wounds/scars 
assessed and photographed under standard conditions. The difference in 
Manchester scar scores between insulin and placebo-treated wounds just failed 
to reach statistical significance. However, the number of patients in this study 
was too few for robust statistical analysis.  Nevertheless, in a number of 
patients, there was a marked asymmetry between the two differently treated 
sides, with the insulin-treated wounds scoring better and being dramatically 
flatter than placebo. It was concluded that the data justified opening a larger 
phase 2 clinical study to determine the efficacy of insulin as a treatment to 
reduce the formation of scar tissue 1.   
 
We also decided to research the feasibility of a new methodology to assess 
cutaneous scarring alongside an established scar assessment tool, the 
Manchester scar scale. Although currently there are several scar 
measurement scales/devices (both subjective and objective in nature) 
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available to the clinician to assess scars, there is however no consensus 
within the literature as to the most effective method, with most methods 
having substantial limitations 4. Most scar scales are validated and 
demonstrate acceptable consistency and reliability, yet they rely on ordinal 
data with relatively few levels. As a result these scales may have limited 
sensitivity i.e. are generally not as effective in establishing small differences 
between different scars and many visually distinct scars may fall into the 
same category 5 6. Since clinical scar assessment lacks a standardized 
methodology and systematic approach there is a clear need to establish an 
optimal, universal scar scoring system in order to characterize and treat 
cutaneous scarring.  
 
HYPOTHESIS   
We hypothesise that a single low-dose of insulin injected to the subcutaneous 
tissues of a surgical incision at the time of surgery will improve the 
appearance of subsequent scarring compared to a placebo injection in 
patients undergoing bilateral breast surgery. The medial 3cm of the sub-
mammary incision will be injected with either insulin or placebo in order to test 
this hypothesis. The assessment will be conducted within the context of a 
randomised, double blind, intra-patient, placebo controlled trial upon patients 
who are scheduled to undergo bilateral breast surgery for medical or aesthetic 
reasons who have given their consent.  
 
We further hypothesise that the accurate quantification of scar colour within 
these patients can be calculated from both digital photographic images taken 
 15 
using a standard digital camera and from a handheld three-dimensional 
photographic device using colour analysis software.  
 
 
INTRODUCTION 
 
In this introduction the normal physiological processes involved in human 
wound healing and cutaneous scar formation will be examined, including the 
key cellular events involved. Scar assessment models, problematic 
pathological scarring, current scar treatments, as well as previously 
conducted work on the anti-scarring properties of insulin, will also be 
discussed. 
 
Introduction to Wound Healing 
 
Skin, the largest body organ, which is responsible for protecting individuals 
from desiccation, temperature variation and infection also plays important 
roles in metabolic, immune, and sensory functions. Wound healing culminates 
in the re-epithelialisation of the skin and scar formation, restoring its essential 
barrier function 7. Thus the ability of humans to heal injured cutaneous tissues 
is essential for survival. Wound healing is not however a fixed process, rather 
it may be considered a dynamic process that adapts to the nature and 
severity of the injury and is itself bound by physiological limitations imposed 
by the age and vitality of the individual 7.  
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Normal Adult Wound Healing & Scar Formation 
 
Adult wound healing is a complex process involving a cascade of cellular events 
and interactions that are coordinated by a myriad of biochemical messengers. 
Cutaneous scarring is the inevitable cumulative event of the wound healing 
process following damage to greater than 33.1% thickness of the dermis 8. 
Scars form in adults because unlike lower vertebrates, such as the salamander, 
tissue injury does not result in complete tissue regeneration. Rather the tissue 
defect is repaired secondarily to the inflammatory immune response, resulting in 
fibroblastic collagen secretion and myofibroblast wound contraction 7. Whilst this 
is an efficient response to injury in terms of whole organism preservation, 
healing by scarring does not restore full function to the injured tissue and indeed 
may compromise function significantly 7. A cutaneous scar therefore may be 
defined as dermal fibrous replacement tissue resulting from a wound that has 
healed by resolution rather than regeneration 9. 
 
Wound healing is traditionally described in terms of three discrete physiological 
phases: inflammation, proliferation, and remodelling (or maturation) 10. However 
this traditional view may be somewhat misleading as the phases exhibit much 
overlap between them and individually consist of highly organised and complex 
series of events at the cellular and biochemical levels (Figure 1) 11. 
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Figure 1: Model showing the overlapping phases of wound healing. Adapted from Clinimed® 11 
 
Haemostasis and Inflammatory Phase of Wound Healing 
 
Establishment of haemostasis and the induction of the acute inflammatory 
process are the immediate physiological responses to cutaneous injury. The 
inflammatory phase persists over the next 4-6 days 12. The priority action the 
body initiates following tissue injury is to control haemorrhage through 
localised vasoconstriction mediated by the sympathetic nervous system and 
cellular release of thromboxane A2 and prostaglandin 2-α 12,13. The intrinsic 
clotting cascade is simultaneously activated via exposure of endothelial 
elements and platelet activation to induce clot formation and halt 
haemorrhage 12–14. The resulting clot is composed of platelets, collagen, 
thrombin and fibronectin, and these elements release cytokines that are 
responsible for the propagation of the inflammatory response. The clot further 
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functions as a scaffold for the incoming inflammatory cells such as neutrophils 
and monocytes 12–14. 
The early inflammatory phase is characterised by the arrival of the effector 
cell of the acute inflammatory state; the neutrophil. Neutrophils migrate to the 
area by a process of margination, pavementing, and diapedesis through the 
vasodilated capillary networks 15. Neutrophils accumulate in response to 
released cytokines, especially TNF-α, TGF-β, the complement component 
C5a, and those propagated from bacterial matter 16. Migration through tissues 
to the wound site is via a chemotactic response to these cytokines along 
concentration gradients 16. Once activated, neutrophils release proteolytic 
enzymes, phagocytose foreign material, and secrete pro-inflammatory 
cytokines 17. Over the next 48-72 hours neutrophils begin to undergo 
apoptosis and monocytes diapadise the endothelium to become macrophages 
which accumulate and become the predominant cell type 18. Macrophages 
importantly secrete enzymes (principally collagenases), which degrade the 
damaged extracellular matrix allowing subsequent wound healing. 
Macrophages also release cytokines (IL’s and TNF) which stimulate 
fibroblastic activity, promote angiogensis and directly phagocytose cellular 
debris 18.  
Proliferative Phase of Wound Healing 
 
In the normal wound healing environment few inflammatory cells are present 
1-week post-injury and the so-called proliferative phase becomes the 
dominant process 18. The proliferative phase actually begins approximately 4 
days post-injury and persists for up to 14 days. This phase is characterised by 
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epithelialization, angiogenesis, granulation tissue formation, and collagen 
deposition by fibroblasts 18.  
Proliferation of epithelial cells located on the periphery of the wound in 
response to EGF and TGF-α secreted from activated platelets and 
macrophages is an early process in wound healing where the basement 
membrane has been breeched and is an attempt to establish a barrier 
protecting against desiccation and further contamination 19. The inflammatory 
cytokines IL-1 and TNF-α stimulate fibroblasts to produce KGF-1, KGF-2, and 
IL-6 which promotes keratinocyte migration, proliferation, and differentiation to 
restore the integrity of the dermal layer 20,21.  
Angiogenesis is on going throughout the proliferative phase of wound healing; 
VEGF and bFGF are secreted from endothelial cells, macrophages, and 
keratinocytes to facilitate this process 12,22. Additionally NO is generated by 
the endothelial cells secondary to the hypoxic conditions created by the 
devascularised tissue(s) which further stimulates the production of VEGF and 
bFGF and subsequently increases the rate of angiogenesis 12,22. 
Angiogenesis ultimately allows the formation of granulation tissue to begin 7. 
Granulation tissue, so called because of its granular appearance resulting 
from invading capillaries, begins approximately 4 days post-injury and is a 
vascular neo-stroma comprised of loose connective tissue, fibroblasts, and 
macrophages 7.  Fibroblasts within the granulation tissue begin to produce 
type 3 collagen initially in response to PDGF and EGF and subsequently by 
paracrine and autocrine self-regulation. Fibroblasts present within the injury 
site can also be triggered, by PDGF and TGF-β1-secreting macrophages, to 
transform into myofibroblasts which later aid in wound contraction  22,23. 
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Remodelling and Maturation Phase of Wound Healing 
 
During the remodelling and maturation phase, beginning after the first week 
and continuing for up to a year, the previously haphazardly arranged collagen 
becomes organised into a structured network and wound contraction due to 
myofibroblast differentiation occurs in a continually evolving process 7. 
Fibroblasts secrete mature type I collagen along wound tension lines 
replacing the immature, randomly arranged type III collagen and conferring 
increasing tensile strength to the scar 7. This is arguably the most important 
process of wound healing as problems in the deposition of the mature 
collagen matrix will lead to a reduction in scar strength, although excessive 
deposition may result in a pathological keloid scar 12.   
Whilst the increasing ratio of organised type I collagen present in the scar 
dramatically increases its tensile strength it can never reach the stability of the 
collagen present in uninjured skin 23. Under optimal conditions the tensile 
strength of mature scar tissue may reach 80% of that of uninjured skin, 
compared with 30% at 3 weeks, and only 3% at 1 week 23,24. Scars also 
change in appearance with maturation, especially in terms of their colour 
(though textural and topographical changes are also seen). Scars rarely 
match the original skin colour; rather they tend to show increasing redness 
over the initial months and become either paler or darker when compared to 
the surrounding skin with time 25.    
Factors Influencing Wound Healing & Scarring 
 
A great number of factors are known to influence the speed and indeed the 
success of wound healing and scar formation. Broadly, these factors may be 
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classified into categories: Local factors; Systemic factors; and Iatrogenic 
factors (Figure 1). However it is important to realise that these factors are not 
wholly independent and overlap or interplay between factors is common 26. 
 
Local Factors Systemic Factors Iatrogenic Factors 
Infection Co-morbidities Medication 
Injury Location Nutrition Surgical Management 
Depth of injury Age Topical Agents 
Necrotic Tissue Oxygenation Dressing Choice 
Moisture Ethnicity Timing of Intervention 
 
Figure 2: Factors influencing wound healing 
Infection 
 
One of the major functions of the skin is to act as a barrier to potential 
pathogens, thus when the skin is breached by injury (surgical or accidental) 
pathogens may invade 27. The moist, warm, and nutritious environment of the 
sub-dermal tissues provides an ideal medium for bacterial proliferation and 
colonization. The potential for infection depends on a number of factors such 
as the wound type, circumstances of injury, injury depth, location, tissue 
perfusion, and strength of the host immune response 27. For example a 
controlled surgical incision in a healthy individual is likely to heal without any 
problematic infection whereas a traumatic injury involving environmental 
contamination in an immunocompromised individual would almost certainly 
develop substantial infection 27,28. Whatever the circumstances leading to 
wound infection it has a deleterious effect upon healing. The normal 
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inflammatory phase of healing becomes prolonged, both in time and intensity, 
due to elevation of pro-inflammatory cytokines such as IL-1 and TNF-α 28,29. 
The elevated inflammatory response stimulates increased concentrations of 
proteases (MMP’s) as well as suppressing protease inhibitors resulting in 
increased proteolysis and subsequent degradation of the ECM 28,29.   
Almost all wounds will show some bacterial colonisation if sampled, but for 
those colonising organisms to cause problematic healing a critical microbial 
load must be reached 30.  Evidence suggests that very low levels of bacterial 
colonisation may actually expedite wound healing 29. The landmark studies of 
Robson & Heggers propose that acute wound infection with subsequent 
detrimental wound healing or breakdown results from a bacterial load of >105 
organisms/g of tissue 30–32. More recent work has shown that whilst the critical 
bacterial load may be 105 for most bacteria, some species, such as beta-
haemolytic Streptococci, have been shown to cause wound problems at a 
much lower inoculum 33. Bacteria that are a particular cause of wound 
problems include Staphylococcus aureus, Pseudomonas aeruginosa, and the 
beta-haemolytic Streptococci 27. Clearly all steps possible should be taken to 
avoid the inadvertent exposure of wounds to bacteria when performing 
elective surgical procedures and traumatic wounds must be effectively 
decontaminated to prevent opportunistic infections and avoid wound 
breakdown 28,33. 
Injury Location 
 
There may be considerable variation between anatomical locations, even 
within the same individual, in wound healing rates and subsequent scar 
formation 34. Typically wounds heal faster and exhibit minimal scarring upon 
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mucosal surfaces such as the oral cavity, whereas the deltoid and pre-sternal 
regions frequently develop heavy or pathological scarring following injury 3. 
This is a direct result of the differing biological and mechanical stresses at 
these anatomical locations 3.   
Surgical Management 
 
Wounds may heal by either primary or secondary intention. Healing by 
primary intention refers to wounds that have undergone surgical closure, 
whereas secondary intention healing describes a process where open 
wounds are left to heal by tissue regeneration and wound contraction 35. 
Surgical closure minimises wound size by closely approximating the wound 
edges thereby reducing the area required to heal and expedites wound 
healing which will principally occur by means of rapid epithelialisation and 
connective tissue deposition 35,36. In contrast to secondary intention healing, 
there is little granulation tissue or wound contraction in this process 36. 
Surgical closure is usually taken to mean direct approximation of tissues by 
means of suturing but can also mean the use of various specialised 
techniques such as skin grafts, local tissue flaps, or free tissue transfers 35.  
Meticulous aseptic surgical technique will expedite wound healing and 
minimise scar formation. Delicate tissue handling, thorough haemostasis, 
tension free closure, and the use of the finest gauge sutures compatible with 
the strength required are all crucial elements 36. Where possible, surgical 
incisions should be placed in the so called relaxed skin tension lines (RSTL’s). 
These lines were first described by Borges in 1962 and follow the furrows 
formed when the skin is in a relaxed state 37. They are not however a visible 
skin feature such as wrinkles (although they commonly coincide with them), 
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however surgical incisions located in RSTL’s minimise both wound tension 
and scarring 37. Alternatives and adjuncts to the traditional method of suture 
skin closure, such as octylcyanoacrylate glue and the use of paper tape, may 
also improve some surgical scars 38,39. 
Depth of Injury 
 
It is well known that not all cutaneous injuries result in scar formation, with 
many cuts or abrasions leaving no long-term stigmata. Rather contradicting 
this truism however, it is also anecdotally maintained that all surgical incisions 
will leave a scar 18,40. Clearly both positions cannot be wholly accurate and 
there exists a correlation between the depth of cutaneous injury and the 
production of macroscopic scar tissue. Forester & Jaques attempted to 
quantify the precise depth at which injury would result in scarring using a 
porcine model 41. Their results suggested that macroscopic scarring would be 
apparent only when incisions extended through the dermis into the 
subcutaneous fat and more superficial (intradermal) injuries do not produce 
macroscopic scars 41. An important aspect to consider is the concept of 
macroscopic (visible) scarring. It is a noteworthy point, as many studies 
recognise that a controlled injury to the papillary (upper) dermis, similar to 
those produced during routinely performed cosmetic procedures, such as 
chemical peels or dermabrasion, produce histological evidence of scar tissue 
but importantly leave no macroscopic evidence of scarring 42.  Similarly in a 
limited sense the process of tissue regeneration and scarring can occur in the 
same adult tissues. For example if a large portion of the human liver is 
resected during surgery it will completely regenerate with no observable 
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scarring yet the same liver will heal by fibrosis if a small stab incision is made 
to its parenchyma 43.   
A more robust analysis was provided by Dunkin et al, where 113 volunteers 
were incised in a continual fashion using a graduated depth cutting jig over 
the lateral aspect of their hip from the superficial to the deep dermal layers 8. 
Subjects were followed up for a total of 36 weeks and results were recorded 
by means of digital photography and high frequency ultrasound. This study 
identified a critical threshold depth of injury that would result in a scar. This 
figure is taken to be 33.1% or 0.5mm of normal hip skin thickness 8.  
However the results of Dunkin et al should be interpreted with caution, as the 
study does not address if scarring is dependent upon a physical depth of 
injury (0.5mm) or an overall percentage thickness of injury (33.1%). This is an 
important distinction, as would a 0.5mm deep incision in thicker skin, e.g. that 
found on the scalp or back, result in scarring, or is it required that 33.1% of 
the dermal depth must be incised? In a similar manner it is well known that 
the harvest of a split thickness skin graft will typically produce scarring even 
though the depth of injury is much less than 0.5mm 44. This would appear to 
suggest that it is not only injury depth that is important in determining scar 
formation but also the width or surface area of the wound and the time taken 
for the wound to heal. 
Significant Co-morbidities 
 
A magnitude of illnesses may impact upon the wound healing process and 
must be considered a potential aetiology of the slowly healing wound. A full 
discussion encompassing all of the differing pathologies that can potentially 
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influence wound healing is beyond the scope of this thesis but some of the 
most relevant disorders are discussed below- 
Diabetes Mellitus: The effects of diabetes upon wound healing can be 
significant and multi-factorial. Diabetes impacts the circulatory system causing 
both micro- and macrovascular pathologic changes, which result in, reduced 
tissue perfusion and oxygenation 45,46. The microcirculatory disruption may 
also damage neurons producing sensory neuropathies that predispose to 
repeated tissue injuries and chronic wounds 45,47.  Diabetic patients also suffer 
with immune impairment secondary to the detrimental effects of 
hyperglycaemia upon leukocytes, thus are more prone to infection and evoke 
sub optimal responses to invading wound organisms 45. 
Hypothyroidism: Hypothyroidism is known to impair wound healing both 
directly through interference with fibroblastic collagen production and 
indirectly through the systemic manifestations of the disease such as 
cardiovascular failure and immune impairment 48,49. 
Organ Failure: All types of organ failure will impact negatively upon 
wound healing by various means. Particularly relevant are gut failure 
(inadequate nutritional status), hepatic failure (reduced plasma proteins, 
clotting factors, and glucose disregulation), renal failure (metabolic toxic state 
and down regulation of immune cells), and cardio-respiratory failure 
(inadequate tissue oxygenation) 50 
Congenital Disorders: A variety of hereditary conditions disrupt wound 
healing by means of defective collagen and connective tissue production 
including Pseudoxanthoma elasticum, Ehlers-Danlos syndrome, Cutis laxa, 
and Werner syndrome, amongst others 51.  
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Oxygenation and Tissue Perfusion 
 
Healing wounds require adequate tissue perfusion in order to deliver oxygen 
and nutrients, as well as facilitating local immune responses. Wounds will 
typically heal rapidly if the oxygen tension is more than 40mmHg but healing 
is unlikely to occur at all if the oxygen tension falls below 20mmHg 52. Oxygen 
is essential to allow normal intracellular aerobic metabolic processes and 
ischaemic (anaerobic) metabolic changes can be seen in tissues at oxygen 
tensions of 30mmHg 52. The anaerobic metabolism generated in low oxygen 
tensions fails to generate sufficient energy for the healing wound and as a 
result fibroblastic proliferation, collagen synthesis, exportation of collagen 
from the fibroblast cell membrane and re-epithelialisation, are all inhibited 53–
57. Low oxygen tensions not only deprive a wound of required nutrients but 
allow the invasion and colonisation of the wound by microorganisms 57. A 
variety of physical and environmental factors may reduce oxygen tensions 
e.g. high altitude, smoking, cardio-respiratory disease, anaemia, and various 
other blood disorders. Similarly there is much evidence to suggest that 
artificially increasing the oxygen tension by means of hyperbaric oxygen 
therapy expedites healing in a variety of wound types 58–60.  
Nutrition 
 
It is well recognised that generalised malnutrition, or indeed specific nutrient 
deficiencies, may have profound detrimental effects on wound healing and 
scar formation 50. In short, wound healing requires sufficient reserves of all of 
the major food groups (protein, carbohydrates, and fats) as well as 
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micronutrients and vitamins. Especially important however are adequate 
reserves of protein, certain amino acids (glycine, glutamine, arginine), trace 
metals (zinc, copper, selenium, iron, magnesium, manganese), vitamins (A, B, 
C, E), and ascorbic acid 50.   Malnutrition is a frequent cause of non-healing 
wounds and affected individuals require directed nutritional therapy to allow 
sufficient collagen deposition and robust scar formation to develop 61,62. 
Indeed, it has been demonstrated that humans may only require a very 
modest protein-calorie malnutritional state before fibroplasia is inhibited and 
healing is impaired 63.  
Age 
 
Wound healing and age are intrinsically linked, and marked differences in the 
process exist across ages. In adult tissue the scar is the end result of the 
wound healing process, yet the early fetus heals by complete regeneration 
and does not scar at all 7. Differences do not just exist between the fetal and 
adult model, the wound healing process differs from the young child through 
to individuals of old age quite markedly 3. It is well recognised for example 
that the elderly exhibit diminished wound healing abilities compared to 
younger subjects, and there are a number of physiological and pathological 
factors such as epidermal thinning, diminished immune responses, altered 
cytokine profiles, vascular disease, and poor nutrition levels that are 
responsible for this observation 64–66. However, somewhat paradoxically, there 
is considerable evidence to suggest that the elderly exhibit cellular 
mechanisms that result in significantly diminished scarring. It seems likely that 
the speed of wound healing in the young is increased at the expense of scar 
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quality due to these changes with the most intense scarring being observed 
during the adolescent and early adult years 3. 
In the adult, wound healing culminates in scar formation i.e. it is a 
fibroproliferative process without substantial regeneration of original tissues 12. 
In stark contrast to this is the remarkable ability of early gestational fetuses to 
heal wounds in a scarless manner with complete regeneration of the injured 
tissues 67,68. Scarless healing only occurs in the relatively young fetus (<24 
weeks) thereafter wounds begin to heal by scar formation, the size of the 
injury is also important and very large wounds may not heal in a scarless 
fashion, even in very early gestation 67,69. Initially it was thought that scarless 
healing was secondary to the sterile, nutrient rich amniotic fluid environment 
of the fetus. However this has been proven not to be the case by Lorenz et al 
who showed it is possible for fetal skin to heal without scarring outside of the 
womb when transplanted onto donor organisms 69. There are however a 
number of physiologically unique properties that the early fetus exhibits that 
promote scarless (regenerative) healing- 
Fetal Skin: The extracellular matrix (ECM) plays an important role in 
wound healing in both the fetus and the adult and in both consists of a 
dynamic layer containing collagen, glycosaminoglycans, amionoglycans, and 
adhesion proteins 7. Fetal ECM differs from adult ECM in terms of its collagen 
composition (increased ratio of type 3 to type 1 collagen), has higher 
hyaluronic acid concentrations, and shows increased activity of ECM 
modulators such as fibromodulin which inactivate TGF-β 7,68,70. The fetal skin 
is also in a state of rapid expansion and development leading to a high 
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concentration of morphogenic and growth factors that is substantially different 
to adult skin 71.  
Fetal Cells: Like the adult model a variety of fetal cells are involved in the 
healing process. However there is an important distinction, the overwhelming 
observable difference in fetal healing is the distinct lack of an inflammatory 
response 7. This is a reflection of the fact that the fetus physically has a 
different immune system to the adult as it is still developing and as such the 
response to injurious stimuli differs. Embryonic injuries have fewer 
inflammatory cells e.g. neutrophils and macrophages etc and those that are 
present are markedly less differentiated resulting in a reduced intensity and 
duration of acute inflammation within the wound 7,71. The fetal wound is also 
markedly deprived of platelets in comparison with that of the adult 71. 
Fetal Growth Factors & Cytokines: As previously mentioned, fetal skin 
is developing rapidly and contains a variety of different morphogens and 
growth factors. The profile of these growth factors and cytokines differs from 
the adult in terms of not only the actual factors present within the wound, but 
also in the concentration and duration of action of some of the common 
molecules 71. Due to the relative lack of platelets in the fetal wound PDGF is 
virtually absent, whereas it is prominent in the adult wound secondary to 
platelet degranulation. Instead fetal wounds have high concentrations of 
FGF’s which are morphogenic in nature 72.  
Possibly the most studied growth factors within the literature however are 
the various isoforms of TGF-β which are multi-functioning growth factors. It 
has been well demonstrated in experimental models that the fetal healing 
wound contains extremely high concentrations of TGFβ3 and low levels of 
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TGF-β1 and TGF-β2, whereas the adult wound contains mostly TGF-β1 and 
TGF-β2 71–74. The source of the TGF-β secretion also differs in the two 
models. In the fetus it is secreted predominantly by keratinocytes and 
fibroblasts whereas in the adult secretion is from degranulating platelets and 
inflammatory cells 71. The differing levels of TGF-β isoforms in the fetus may 
well be relevant in the non-, or minimal scarring models. Experimental 
evidence suggests that altering the ratio of TGF-β isoforms through the 
addition of exogenous TGF-β3 to an adult (rat) wound model to raise the ratio 
of TGF-β3 towards a more “fetal level” reduced scar formation 75. This clearly 
suggests that ratio of TGF-β isoforms within a wound are important, and 
specifically that a raised TGF-β3 ratio may drive scarless healing in the fetus 
i.e. it is an antifibrotic isoform whereas TGF-β1 and TGF-β2 may be 
considered to be the profibrotic isoforms 76. Indeed the overexpression of 
TGF-β1 and TGF-β2 is strongly associated with pathological fibrotic 
conditions and cancer in the adult 71,76–78. The interaction between the various 
TGF-β isoforms and the fetal fibroblast is however complex and experimental 
evidence suggests that although very similar TGF-β signalling pathways and 
identical intracellular (Smad) signalling pathways exist between the fetal and 
adult models the fibroblastic response differs and more research is needed to 
understand these interactions and responses further 76. What the literature 
does suggest however is that restoration of a more “fetal balance” of TGF-β 
isoforms within an adult wound would likely be beneficial and could form the 
basis of therapeutic interventions 77. 
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Interleukin cytokines are important in initiating the inflammatory immune 
response both in terms of chemotaxis and inflammatory cell activation. It is 
notable that in the fetus the response to interleukins, especially IL-6 and IL-8, 
is substantially blunted compared with the adult 7. The fetus exhibits both a 
reduced level of expression but also reduced duration of IL-6 and IL-8 
exposure 7. 
It is clear that there exist many differences between adult and fetal wound 
healing and it would appear that scarless healing is unique to the early fetus. 
This is likely due to processes involving the complex array of growth factors, 
cytokines, and cell signal pathways in the early fetus. However further 
understanding and research is required to translate some of these observable 
differences into clinically useful scarless therapies. 
Pathological & Problematic Scarring 
 
In terms of classification there are 5 main types of cutaneous scarring: Fine 
line or “normal”; stretched; atrophic; contracted; or raised 40,79. However in 
clinical practice what may be described as “normal” or “problematic” or 
“pathological” scarring may not always be so easily defined due to 
confounding physical and psychological factors. For example a scar that 
medically speaking is healing in a normal “fine line” fashion may still cause 
itching, pain, anxiety, depression, and prevent normal activities of daily living 
of the patient 80. Similarly defining a contracted scar as problematic may be 
considered somewhat of an oxymoron as all scars contract as part of the 
normal healing process 12. Thus scar contraction generally causes problems 
only if the scar crosses a mobile joint line restricting movement (see below) 81. 
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Indeed scarring resulting from either surgery or traumatic injury can result in 
functional, aesthetic, and psychological consequences for those afflicted.  
Functional problems associated with scarring mostly refer to contractures 
(across joints or mobile tissues) and tend to occur following burns or traumatic 
injuries, typically affecting the upper limb 82. The precise impact contractures 
can have upon those affected depends upon the anatomical location of the 
contracture as well as its severity, but generally speaking contractures of the 
upper limb result in impaired fine motor skills and difficulty feeding or 
grooming, whereas lower limb contractures tend to affect mobilisation 83. Scar 
contractures are not an insignificant problem, over 1/3 of patients with a 
significant burn injury will develop a contracture at the point of hospital 
discharge which not only carries the physical limitations imposed but almost 
certainly will necessitate further treatments and surgery in the future 82,83. 
Other physical manifestations of scars that may affect patients include pruritus 
and pain both of which are known to cause substantial morbidity to those 
affected 84. A large number of people may be affected by these problems-a 
study involving over 500 patients investigating the incidence amongst burn 
patients found that up to 87% of adults and 100% of children are affected by 
both pain and pruritus 82,85. Surprisingly scar itching commonly persists over a 
2-year period and in itself can be an predecessor to the development of post-
traumatic stress disorder 85. Such psychological consequences following 
scarring are not limited to those affected by burn injuries. Patients who have 
sustained scars through trauma, reconstructive surgery, or indeed minor 
elective surgeries exhibit higher levels of psychological morbidities such as 
anxiety, depression, loss of self esteem, post-traumatic stress disorder, sleep 
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disturbance, and psychosexual disorders 3,86,87. Precise reasons for the high 
incidence of psychological disorders seen following scarring is not fully 
understood, especially in cases of small or relatively minor scars but it likely 
relates to the perception of the patient that they now appear aesthetically 
unpleasant or reminds the patient of a traumatic period in their life 88. 
 
Hypertrophic & Keloid Scarring 
 
Abnormally raised scars may be described as either hypertrophic or keloid, 
depending on the scar characteristics 89. The terms are often (incorrectly) 
applied interchangeably as both hypertrophic and keloid scars are distinct 
entities. By definition a hypertrophic scar remains within the dermal 
boundaries of the original cutaneous defect whereas keloid scars spread 
(often dramatically) beyond these boundaries 3,90. Confusingly, the presence 
of both scar types may occasionally be observed within a single scar, or 
indeed one or the other within an otherwise normal scar (Figure 3) 3,90. 
Various factors have been implicated in the pathogenesis of hypertrophic and 
keloid scarring including abnormal up-regulation of collagen synthesis and 
growth factors as well as genetic influences and local factors such as high 
wound tension or infection 91–93. 
Hypertrophic Scars: These are abnormally raised scars that do not 
extend beyond the original zone of injury (Figure 3). Hypertrophic scars 
typically occur rapidly after injury (<4 weeks) and undergo, at least in part, 
some spontaneous resolution 94,95. The exact incidence of hypertrophic scar 
formation is difficult to ascertain with quoted incidences differing across 
published series and results are, in any case, influenced by the mechanism of 
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injury. The literature states the incidence of hypertrophic scarring varies 
somewhere between 33% to 91% with the greatest incidence seen following 
deep burn injuries 18,96–99. Similarly the precise pathogenesis of hypertrophic 
scar formation is not fully understood, but the scars do exhibit differing 
histological and biochemical characteristics compared to normal scars 100. 
Importantly the development of hypertrophic (and keloid) scars appears to be 
dependent upon TGF-β activity which itself is regulated via the 
cyclooxygenase pathway. It has been shown that hypertrophic scars exhibit 
significant overexpression of COX-1 which may result in an abnormal 
epithelial/mesenchymal interaction which increases the activity of dermal 
fibroblasts101. 
 
Figure 3: A hypertrophic scar (black arrow) in the proximal third of an otherwise 
physiologically normal fine-line scar. Picture taken from stock images 102. 
 
Keloid Scars: Keloid scars are a phenomenon unique to humans. The 
word keloid derives from the Greek chele, meaning crab claw, which 
describes the way in which keloids invade local tissues 18. Keloid scars extend 
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beyond the confines of the original wound and show a marked propensity to 
progress in severity and frequently recur following treatment 103. Keloids may 
be observed in all ethnic groups although dark skinned individuals form 
keloids 15 times more frequently than fair skinned people, also they are most 
likely to occur between the ages of 11-30 years, and show a predominance of 
occurrence on the chest, shoulders, upper neck, and earlobes 104. 
Histologically keloids show abnormally stretched collagen bundles in a 
swirling nodular pattern 3,18. Like hypertrophic scars, the pathogenesis is not 
fully understood but clearly involves a combination of abhorrent genetic, 
physiological, and biochemical processes. Central to keloid development is 
their hyper-responsiveness to TGF-β within the injured tissues 101. Similar to 
hypertrophic scars this may be due to abnormal cyclooxygenase activity, 
although it appears that in the case of keloids it is the COX-2 pathway that is 
significantly overexpressed 101. Fibroblasts within keloid scars also show 
markedly lower rates of apoptosis compared with “normal” fibroblasts and 
demonstrate a down-regulation of apoptosis or tumour suppressor genes 
such as p53 and p63 which predisposes to unchecked proliferation 105,106.  
 
Atrophic & Stretched Scars: This form of pathological scarring is 
characterised by thinning of the skin due to loss of collagen, elastin, and deep 
dermal fat, typically by an excessive inflammatory state or skin tension 3. This 
results in a downward pull of the epidermis creating a “pitted” or “hollowed” 
appearance. This kind of scarring is most commonly seen following severe 
acne, pregnancy (stretch marks), and in some pathological conditions such as 
Cushing’s syndrome 3. 
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Scar Assessment Tools 
 
 
Given the diverse phenotypic spectrum observed within the process of human 
scarring and its associated functional, psychological, and cosmetic 
implications for the patient there clearly exists a need for clinicians and 
researchers to be able to accurately assess and classify cutaneous scarring. 
Indeed, many attempts have been made to develop effective scar assessment 
tools or devices and some of which are frequently utilised, not only to provide 
clinical monitoring, but actually to direct therapeutic treatment 107.  
 
Phenotypic Scar Qualities  
 
 
There are a variety of phenotypic characteristics exhibited by scars that may 
be measured or quantified in order to form the basis of a scar assessment tool 
including; colour, thickness, height, volume, surface area, pliability, texture, 
and various physical/psychosocial effects (Figure 4) 108. That is not to say that 
not all of these characteristics need form part of an effective assessment tool 
however and indeed many of these terms overlap, but one needs to consider 
carefully what elements can be accurately recorded in a reproducible, 
quantitative, and most importantly clinically useful way to evaluate scarring. 
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Scored Parameters VSS MSS OSAS PSAS SBSES 
Physical Measurements      
• Thickness/height/contour 
     
• Relief/irregularity   
  
 
• Surface area   
 
  
• Pliability/texture/stiffness 
    
 
Appearance      
• Colour 
   
  
• Distortion  
 
   
• Shine  
 
   
• Hatch marking     
 
Symptoms      
• Pain    
 
 
• Itching    
 
 
Opinion      
• Overall opinion   
 
 
 
 
Figure 4: Scar characteristics as measured by the commonly referenced scar assessment 
scales the Vancouver, Manchester, Observer Scar Assessment, Patient Scar Assessment, 
and Stony Brook Scar Evaluation Scales. Adapted from Vercelli et al, 2009 108  
 
Scar Colour & Clinical Measurement  
 
It is a common complaint of those afflicted by scarring that the colour of their 
scars is markedly abnormal and thus colour assessment forms a valid 
component of most scar assessment scales 4,109. Scar colouration is mainly 
dependent upon factors influencing their redness (erythema) such as 
vascularity and oxyhaemoglobin concentrations, factors responsible for the 
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degree of pigmentation such as melanin, bilirubin, and carotene pigment 
concentrations, as well as physical characteristics such as skin thickness or 
texture 107,109,110.  Some of these factors, for example vascularity, are of 
course dynamic and influenced by inflammatory states and thus scar colour 
typically changes with time. Newly formed scars are highly vascular and red 
whereas mature scars are less vascular and pale in appearance 25,108. Scar 
colour may also be indicative of the potential for development of pathologic 
scarring.  Evidence suggests that the degree of scar erythema is indicative of 
its potential for becoming hypertrophic (due to an abnormally high 
microvascular supply), that is, the redder a scar the greater the potential for 
hypertrophy to develop 111,112. The suggestion that scar colour can predict the 
development of a pathological scar combined with the fact a scar markedly 
different in colour from the surrounding skin will be visually prominent and 
possibly distressing for the affected individual highlight the need for accurate 
clinical colour assessment. There are a number of ways in which the colour of 
scars may be assessed- 
 
Simple Visual Inspection: The classification of scar colour by means 
of simple rater observation comprises key parts of the Manchester, 
Vancouver, and Patient & Observer scar scales, as well as some other less 
frequently referenced scar scale systems 113–115. For the most part these 
scales demonstrate acceptable inter-rater variation when assessing scar 
colour by observation. However the acceptable inter-rater variation observed 
may not be because visual inspection is an effective assessment tool, rather 
because the human brain is incapable of reliably quantifying either colour, 
 40 
intensity, and additionally has a poor ability to memorise colours 4,110. This 
leads to the obvious problem that scars exhibiting quite different colours or 
intensities may be placed in the same classification by raters, especially if 
large numbers of scars are being assessed at different time points. 
Furthermore there is no true quantitative data achieved by this method as 
observational data can only be subjective in nature. The advantage of these 
scales is however that they are readily compatible with use in a busy clinically 
environment 108. 
 
Spectrophotemetric, Colorimetric, & Laser Devices: A range of 
specialised instruments have been developed to provide accurate and 
quantifiable assessment of scar colour by means of colorimetry and 
spectrophotometery. Such devices include the tristimulus colorimeter, the 
Minolta™ Chromameter, and the cyberDERM™ DermaSpectrometer 5. A 
review article comparing these devices to each other and to subjective colour 
rating scales concluded that all the devices were superior in the assessment 
of scar colour compared to observational methods and demonstrated good 
inter-device reliability 116. However whilst these devices indeed provide 
quantifiable scar colour data no reference within the literature could be found 
of groups utilising these devices as part of a more universal clinical scar 
assessment scale, rather they have been validated in isolation (usually in a 
research capacity) to determine scar colour as a separate entity and thus one 
must question their routine clinical application. Some other potential problems 
exist with the use of some of these devices in clinical scar assessment. These 
in part mostly relate to the fact that most of the instruments must be held 
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against the skin to record the colour of the scar. Firstly this means that only 
small areas of the scar may be evaluated at any one time and secondly, if the 
instrument physically touches the skin there will be an amount of pressure 
conferred which may cause a blanching effect due to the emptying of the 
superficial capillary network, producing a (falsely) pale scar colour 117. If a 
device cannot record a given variable (colour) without causing alteration of its 
true value then it cannot be useful, no matter how accurately it may record the 
altered variable. Colorimeter devices have also been shown to be unable to 
reliably differentiate components of erythema and pigmentation from skin 
colour unless specialised techniques are used 118. This again suggests that 
routine clinical use of such devices may be limited and they may be more 
suited to specialised research projects that have the time and ability to use 
specialised imaging techniques. Furthermore it has been shown that the 
texture of the area to be analysed may interfere with readings obtained by 
spectrometry, thus the uneven surface of some scars may preclude their use 
119. 
Laser based methods that assess blood flow using red and near infrared 
wavelengths have also been suggested to analyse scar colour 110,120. These 
devices include the laser-doppler (LDI) and laser speckle (LSPI) imaging 
systems and are routinely used to evaluate the depth of burn injuries but can 
also be used to measure scar colour 110. The LDI measures blood flow within 
tissues and creates a 2D colour map based on this flow, whilst the LSPI 
measures blood flow by utilising the coherent light reflected by stationary 
tissues producing a speckle pattern based image 110,120–122. These devices 
have mostly been clinically utilised to assess burn injuries, mainly to 
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determine the depth of the initial burn, as opposed to colour analysis of the 
mature scar. There is little evidence to suggest their routine use in scar colour 
assessment outside of this sphere which limits their usefulness to the clinician 
in normal circumstances.  
 
Digital Photographic Colour Evaluation: Quantification of scar colour by 
means of spectrometry, laser and colorimetry have, as discussed above, 
some technical, reliability, and practicality issues which limit their routine 
clinical use. It should not be underestimated as well the expense of these 
specialised imaging devices which in itself will make them unlikely to be used 
regularly in today’s fiscally constrained National Health Service 87. Some of 
these issues may be circumvented through the use of computerised analysis 
of digital photographs. Digital photographs are routinely taken of patients 
scars in order to record progress and direct treatment and several readily 
available computer programmes exist that are capable of deriving properties, 
such as colour, from the image 6,123. There are three commonly used colour 
derivation systems within computer analysis of colour; RGB, CMYK, and 
L*a*b* colour coordinates- 
RGB & CMYK Models: Colours can be represented or reproduced from 
digital images by computer analysis through the combining of primary colours 
(Red, Green, Blue) i.e. the RGB system, or by using the so called secondary 
colours (Cyan, Magenta, Yellow), together with black (Key), the CMYK system 
110. The RBG system is additive i.e. primary colours are mixed in various 
ratios to produce colours, whereas the CMYK system is a subtractive model 
(Figure 5) 110.  
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Figure 5: The RBG (left) and CMYK (right) colour systems in diagrammatic form 
 
Colour analysis of scars using RGB and CMYK has been shown to 
produce reliable and accurate interpretations of colour using pixel 
averaging programmes, superior to those achieved through simple 
observation 124. It should be noted that the values obtained when using 
these systems do not represent a “true” colour, rather a quantifiable 
representation based on the RGB/CMYK colours; also essentially 
RGB/CMYK systems require the use of colour references to ensure there 
are no confounding problems with photographic standardisation, especially 
of the ambient lighting levels which can alter RGB or CMYK values 4,84,125–
127. The standardisation of digital images is ensured by placing an object of 
known colour(s) within the photograph from which reference can be taken 
in a reproducible and reliable fashion. Widely used standardisation tools 
include the Pantone®, a proprietary colour space, or a Gretag-Macbeth 
colour standard, a chart with colour patches with a spectral reflectance 
mimicking those of natural objects such as human skin and flowers etc, 
(Figure 6) 110,112,128,129. 
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Figure 6: A Gretag-Macbeth colour standard 
• L*a*b* Colour Coordinates: Whilst RBG/CMYK systems are reliable 
for the most part they may be device dependant and they do not “see” 
colour as the human eye does 130. The L*a*b* (Lab) system was 
developed in order to record colour, as does the human eye and to 
produce a perceptually linear colour space 131. Perceptual linearity (or 
uniformity) describes how closely a change in colour corresponds to a 
change in perception by the human eye i.e. 2 red colours, 4 units apart 
in the colour space show the same amount of visual difference as 2 
green colours 4 units apart 130. The Lab system describes any given 
colour within a set of polar coordinates (Figure 6). The a* and b* 
components describe the red-green and blue-yellow colour 
composition respectively i.e. a* describes red-green with a positive 
reading representing a more red colour and a negative reading 
representing a more green colour. In a similar fashion, the b* value 
would represents blue and yellow colours. The finial L* component 
describes the “darkness” of a colour i.e. how close it is to black or 
white. A zero reading of L* indicates pure black and a reading of 100 
indicates pure white (50 would be grey)117,130–132.  
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Figure 6: Illustration of the Lab colour space. Any colour will occupy a specific coordinate 
within this space. 
 
Scar Thickness & Clinical Measurement 
 
The thickness, height, volume, or surface area of a scar are intrinsically linked 
properties and thus for most intents may be considered to describe the same 
physical characteristic as they all relate to the physical bulk of the scar. An 
overt amount of scar tissue constitutes keloid or hypertrophic scars whilst a 
deficiency of tissue produces atrophic scars. Both hypertrophic and atrophic 
scars are causes of anaesthetic and problematic scarring 107.  A number of 
methods can be used to describe or quantify these characteristics- 
Visual & Palpation Assessment Methods: The assessment of scar 
bulk forms a component of most commonly used scar scales with some 
scales showing greater reliability than others 4. For example the Vancouver 
scale shows only moderate reliability in defining scar thickness whilst the 
Hamilton scale shows much better reliability in this aspect 113,133. The 
reliability of simple inspection or palpation methods appears to be related to 
the number of raters with increasing reliability demonstrated in tandem with 
the number of raters 4. This suggests that “crowd wisdom” is very important 
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and all scales utilising visual or palpation methods of assessment may 
actually be all broadly comparable should the number of raters be taken into 
consideration. The data gained from such methods is of course subjective and 
if large numbers of raters are required to demonstrate acceptable accuracy 
then reliable clinical application will be limited.  
Mechanical Assessment Methods: Wide ranges of mechanical aids 
have been suggested as suitable for measuring scar bulk. There are general 
assessment tools such as mechanical profilometers, ultrasound, and 
magnetic resonance imaging scanners which are capable of determining the 
physical volume and surface texture of scar tissues with a good degree of 
accuracy 99,134–136. All of these mechanical aids have a role to play in the 
assessment of scarring but most are bulky, time consuming, and expensive 
which severely restricts their routine clinical use in scar assessment. 
Histological Analysis 
 
Histological scar analysis is not routinely performed outside of the research 
environment as clinicians are focused primarily on treating the macroscopic 
appearance of scars and histological evaluation rarely will aid clinical 
decision-making 7. However in a research environment or within the context of 
a clinical trial histological analysis may be helpful in order to definitively 
distinguish between different forms of pathological scar in terms of collagen 
orientation etc, and in the case of scar treatment analysis, histological 
observations can be used to assess the degree of restoration towards a 
“normal” dermis 7,137,138. The normal wound healing process and scar 
maturation has been described histologically and this allows for clinical 
correlation in the case of anti-scarring treatments 139. Briefly, the epidermis 
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consists of stratified squamous epithelium, the thickness of which varies 
according to the body site. The normal epidermis contains adnexae and 
eccrine glands and forms a characteristic undulating appearance. This 
undulation is due to intermittent but regular protrusions of the epidermis, 
known as rete pegs into the underlying dermis and the pillars of dermis 
adjacent to these rete pegs form the rete ridges 140. Below the epidermis is 
the basement membrane and then the dermis. The dermis is mainly 
composed of (organised) collagen fibres with some elastin, which are bound 
together by a ground substance. The normal dermis will also contain 
abundant nerves, vessels, cells, and adnexal structures 140. Histological 
comment can be made relating to the appearance of pathological or treated 
scars in reference to the state of the rete ridges, dermal integrity, cellularity, 
collagen organisation, and vascularity in comparison to normal or adjacent 
skin 103,137,139,141,142.     
 
Figure 7: H&E stained sections of the normal human dermo-epidermal junction (left) and scar 
tissue (right) taken from a trial participant. Note the featureless, thin dermal junction of the 
scarred tissue compared with the thick, undulating rete plugs and ridges of the normal skin.  
Scar Pliability & Clinical Measurement 
 
The pliability or texture of a scar describes the mechanical properties of a 
scar. The pliability/stiffness can influence the motion of skin and other mobile 
 48 
structures around that scar causing functional impairment in the case of firm 
scars, especially if they traverse joint surfaces or areas of movement 107,108. 
Similarly to assessing scar thickness, pliability measurements may be taken 
either by simple observation or using mechanical methods- 
Palpation Assessment Methods: The palpation of scars to determine 
pliability comprises a key component of several commonly used scar 
assessment tools such as the Manchester, Vancouver, and Patient Scar and 
Assessment scales 113–115. Palpation of scars only provides subjective data 
and wide variations are reported between raters, with increased reliability 
seen with an increased number of raters 143. 
Mechanical Assessment Methods: There are specialised instruments 
that rely on suction deformation measurements such as cutometers which 
have been specifically designed to assess scarring and showing high levels of 
accuracy and good inter-user variability if measurements are taken under 
standardised conditions 4,135,144. These standardised conditions may be 
difficult to replicate in clinical working environments as they relate to 
temperature and humidity constants which are inherently uncontrollable in 
most clinical areas 4,145. Other suggested methods rely upon devices using 
pressure, torsion or tension loading principals, but these are also not 
generally suitable for clinical assessment due to their high cost, invasive 
nature, and complexity 4,108,146. 
Other Features 
 
There are other features of scars that one must consider recording when 
assessing scars that are not demonstrable physical characteristics per se. 
Examples of such scar features would include factors such as itching/pruritus, 
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pain, reduced sensitivity, and psychological distress. All of these symptoms or 
features are commonly described by those afflicted with scarring but are not 
necessarily amenable to (qualitative) observational measurement within 
objective scar assessment and interestingly do not appear to necessarily be 
related to the severity of physical scarring 3,79,147. As these factors have been 
demonstrated to be unrelated to the severity of scarring then their role in the 
objective assessment of physical scarring in clinical situations is debateable. 
That is not to say that these matters are unimportant to the individual affected, 
merely that their inclusion in quantitative scar assessment scales likely does 
not aid objective classification. 
Current Scar Assessment Scales 
 
A multitude of different scar assessment scales exist within the literature that 
attempt to describe some of the above mentioned scar characteristics and it is 
beyond the scope of this piece of work to describe them all although suffice to 
say there is currently no assessment scale available that is appropriate for all 
forms of scar assessment, as all have clinical limitations 108. The ideal 
assessment scale would be non-invasive, quantitative, reproducible, and be 
easy to use in the clinical environment. Within the literature the 5 most 
commonly utilised scales (in the clinical context) are the Manchester Scar 
Scale (MSS), Vancouver Scar Scale (VSS), Patient and Observer Scar 
Assessment Scale (POSAS), Visual Analogue Scale (VAS), and the Stony 
Brook Scar Evaluation Scale (SBSES) 5. These assessment scales are not 
mutually exclusive, for example one of the components of the MSS scale is a 
VAS (which is a scar scale in it’s own right) and as a cohort these scar scales 
share many common features. Because of this commonality there is a large 
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amount of crossover in terms of clinical application, benefits, and 
disadvantages of these assessment systems (Figure 7) 5. 
 
Scale Scoring 
System 
Components 
Analysed 
Disadvantages Advantages 
VSS 0-13 Vascularity, 
pigmentation, 
pliability, & 
height/thickness 
No patient input, 
operator errors, 
excludes pain, 
the pigmentation 
scale may not 
applicable on all 
scars 
Widely used in 
literature as an 
outcome 
measure in burn 
scars 
VAS 0-100 Vascularity, 
pigmentation, 
acceptability, 
contour, and 
observer 
comfort 
Purely photo 
based with no 
patient 
assessment 
Simple to use, 
allows easy 
assessment of 
inter- rater 
reliability 
POSAS 5-50 VSS plus 
surface area 
and 
symptomatic 
patient 
assessment 
Items 
represented 
may not 
represent 
patient concerns 
or perceptions 
Has focus on 
scar severity 
from both 
patient and 
clinician view 
points 
MSS 5-18 VAS plus scar 
colour, skin 
texture, 
relationship to 
surrounding skin 
texture, 
margins, size, 
and multiplicity 
Rather arbitrary 
assessment 
Applicable to a 
wide range of 
scars. 
Description 
relate closely to 
clinically 
significant 
aspects 
SBSES 0-5 VAS plus width, 
height, colour, 
presence of 
suture marks 
Purely photo 
based with no 
patient 
assessment. 
Not designed for 
long-term scar 
assessment 
Well suited to 
assessing the 
short term 
appearance of 
repaired 
lacerations 
 
 
Figure 8: Comparison of the most commonly utilised scar assessment scales. Adapted from 
Fearmonti et al 2010 5. 
 
It can be seen that there exists a great deal of commonality between the 
routinely utilised scar scales. However some scar scales may well be more 
suited to certain clinical situations than others, depending upon what the 
researcher is trying to determine. Fore example if one is attempting to 
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elucidate the psychosocial impact that scarring may have upon individuals 
then it would seem appropriate to use the POSAS as this scale is largely 
designed to assess the patients perception of their scarring, however it may 
well be less useful to use in a situation where accurate measurement of a 
particular scar characteristic is required 82,108. Similarly if one is attempting to 
assess treatment effect in a population of patients afflicted with burn injuries 
then the VSS is likely most appropriate as the scale was specifically designed 
with the intent of assessing burn scar characteristics and has been 
demonstrated within the literature to be a reliable measure of such scars 113. 
However there are some issues with the VSS if one attempts to use the scale 
to assess non-burn scars, especially linear surgical scars as some of the 
scales components e.g. pigmentation may be less relevant in such scars and 
it has been demonstrated that when used to assess linear scars there is a 
relatively high inter-rater variation of scores 108,148. These factors possibly 
make the VSS less suited to this form of assessment. Given some of these 
issues many researchers have opted to use the MSS to assess such linear 
scars 107. The MSS was designed with this form of assessment in mind and 
shows superior inter-rater variability in this regard 114. Also MSS scores have 
been demonstrated to closely correlate to scores assigned by subsequent 
histological analysis of the same scars 114. It is for these reasons that we have 
decided to use the MSS score as part of our scar assessment in this study. 
Need for Continued Development of Scar Assessment 
Scales & Tools 
 
As with many areas within science and medicine, several assessment or 
classification systems are available to the clinician to be used in scar 
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evaluation, because no one single scar assessment scale or device currently 
exists that is suitable for all assessment purposes 107. Scar assessment, 
especially in the clinical context, frequently lacks a methodical approach and 
this is reflected within the scientific literature where it is difficult to find any 
consensus agreement upon a current ideal or universal scar assessment tool 
5. These issues are likely a reflection of the huge phenotypic variability that 
exists within scar types. For example, a fine-line, small and electively placed 
surgical incision scar is an entirely different phenomenon to a pathological 
keloid scar developing within an extensive burn injury. Indeed many of the 
currently available scar assessment devices in routine clinical use were 
devised with the intention of assessing burn scars as opposed to elective 
surgical incisions 108. Similarly, it would appear that some of the current 
assessment tools are incompatible with routine use in busy medical clinics 
due to time constraints, which potentially limits their use outside of a research 
setting. The ideal clinically useful scar assessment device (or scale) would be 
quick and easy to use, non-invasive, and collect relevant, objective data in a 
reliable and reproducible fashion 5. Such a tool would allow clinicians to 
incorporate a reliable quantitative assessment of scar characteristics 
alongside their clinical judgement to guide therapies and assess response to 
treatment. Furthermore, in today’s increasingly litigious and financially fiscal 
times a reliable scar assessment tool could help to validate and justify a 
clinician’s chosen treatment of any given patient.  
Current Scar Therapies 
 
A vast amount of literature has been published over the years relating to a 
wide variety of scar treatments, a simple search on PubMed returns more 
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than 47,000 articles using the term “scar treatment” alone. A common 
problem within the literature around scar treatments is a poor evidence basis 
for many of the described treatments due to such problems as a lack of an 
appropriate control group, lack of randomisation, heterogeneity of the scars 
assessed, lack of appropriate follow-up, and the use of unreliable or un-
validated assessment scales. Clearly it is beyond the scope of this work to 
mention all available treatments but the most commonly clinically recognised 
treatments with sound experimental evidence behind them will be discussed 
briefly.  
Pressure Therapy & Massage: Pressure therapy and massage have 
been used as a scar therapy for many years now 149,150. Pressure and 
massage is believed to accelerate scar maturation by reducing blood flow and 
oxygen which creates a hypoxic environment which in turn thins the epidermis 
due to a reduction in fibroblastic activity and collagen deposition 149,151. Much 
of the evidence base surrounding pressure therapy is weak although most 
reports suggest pressure should be maintained between 24-30 mmHg for long 
periods of up to a year and there are no specific guidelines regarding 
massage therapies 152. However most large studies that have been conducted 
fail to show a significance difference in either accelerated recovery time or 
improved cosmetic outcome and as such pressure therapy or massage is 
rarely recommended as a stand-alone therapy, at least for pathological scars 
in any case 149,152–154.  
Silicone Gel: Silicone gel sheets and to a lesser extend “free” silicone 
gel or cream are widely described in the literature as appropriate modalities to 
treat pathological scars, often in combination with pressure and massage 
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therapies. The mechanism of action of silicone gel is somewhat controversial 
with some suggesting that it has a hypoxic effect, others that it is a hydrating 
agent, and still others suggesting an alteration of fibroblastic growth factors 
149,152,153. There is much variation in reporting of the efficacy of silicone gel 
however a systematic Cochrane review suggested that there was some 
minimal evidence to suggest silicone may be helpful in the treatment of 
pathological scars but the evidence was mostly unclear and further evaluation 
is required 155.  
Corticosteroids: Steroid injections such as triamcinolone have been 
utilised to treat hypertrophic and keloid scars since the 1960’s and whilst there 
are relatively few, large randomised controlled trial they are widely used as a 
first line treatment 156. Steroids are known to induce many biochemical 
changes in tissues such as reducing fibroblastic proliferation, collagen 
synthesis, and inflammatory mediators however their exact mechanism of 
action upon pathological scar is still not entirely clear 149,156. Intralesional 
corticosteroid injections of 10-40mg/mL (depending on the amount of scar 
tissue), often with two or three successive injections over time shows variable 
response rates of between 50-100%, with a subsequent recurrence rate of 9-
50% 156. Although a relatively safe treatment, steroid injections are associated 
with significant injection pain and can have adverse effects, especially on the 
local tissues, with up to 63% of patients reporting skin atrophy, 
depigmentation, and telangiectasia following treatment 153,157.  
 Surgery: Surgical treatment of hypertrophic or keloid scars aims to 
remove the pathological tissue and produce a new, non-pathological scar. 
Surgery may also be used to treat problems associated with scars such as 
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contractures or address aesthetic concerns using specialised techniques such 
as skin grafts, the z-plasty, or free tissue transfers. However these techniques 
will not be discussed in detail as they will most commonly be employed in the 
management of normal (but problematic) scars and rarely would be 
considered for use in keloid or hypertrophic scars 149,153. In the case of 
hypertrophic or keloid scars simple excision and meticulous re-suturing 
without undue wound tension may be considered although it is widely 
suggested in the literature that this is not undertaken as a primary 
management strategy, especially if a scar is immature (less than 1 year). Also 
simple excision alone has a recurrence rate of between 45-100% and as such 
it is recommended that excision be combined with a corticosteroid injection to 
reduce the keloid recurrence rate to about 50% 100,153,158–161. Surgery can also 
be combined with other treatment modalities such as radiotherapy although 
one must carefully consider their use 100,161. 
 Radiotherapy: As a stand alone treatment for keloids and hypertrophic 
scars radiotherapy is relatively controversial due to concerns of inducing 
neoplastic change in irradiated tissues and the relatively poor results 
described; response of keloids to radiotherapy is reported to be 10-94% with a 
recurrence rate of 50-100% 153,159,161. Recurrence rates improve to between 
16-27% with radiotherapy if it is given in combination with surgical excision, 
however the evidence base for this is relatively poor and a more recent study 
has suggested that recurrence rate is more than 71% in a large cohort 
followed up for only 9-months 162–164. Other than concerns relating to 
malignant transformation, irradiated tissues may atrophy, undergo pigment 
change, or develop erythema 149. Further study is required to ascertain the 
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safety, efficacy, and what the effective dose of radiotherapy is and presently it 
is recommended with caution as a treatment for keloids in the majority of the 
literature 160. 
Lasers: Laser therapy is not a single treatment modality, a range of 
lasers exist such as the Nd:YAG, CO2, PDL, and Argon lasers and they have 
been advocated for treating everything from a well healed surgical incision to 
atrophic scars to treatment resistant keloids165,166. As such, despite numerous 
studies being published relating to laser scar treatments, there remains a 
paucity of definitive evidence relating to efficacy, recurrence rates, and 
treatment risks and further research is recommended 149,165–168.   
TGF-β3 Therapy: Much excitement surrounded the utilisation of TGF-
β3 related therapies due to the known importance of the isoform in the fetal 
scarless model. Indeed two large stage I/II, randomised placebo controlled 
trials injecting avotermin (recombinant, active, human TGF-β3) intradermally 
to electively placed incisions showed significant improvement in scar 
appearance compared to control 169,170. However the phase III trail involving 
more than 350 patients across multiple centres in Europe failed to reach 
statistical significance in either its primary or secondary endpoints and as 
such the future of TGF-β3 as an antiscarring agent are uncertain 171,172. 
Other Therapies: A multitude of other scar therapies are described 
within the literature in clinical use around the world. Such agents include 
chemotherapeutic drugs such as 5-flurouricil and Bleomycin, cryotherapy, 
onion extract, imiquimod, COX-2 inhibitors, as well as many others. All of 
these agents have relatively low evidence levels to suggest their efficacy and 
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some treatments may carry the risk of significant side effects and as such 
caution is suggested 149,152,153,173,174. 
The Need For Continued Research Towards 
Development of an Effective Anti-Scarring Agent 
 
It can be seen that a large number of therapeutic modalities have been 
developed over the last 30-40 years to treat pathological scarring and 
numerous attempts have been made to produce products that reduce or even 
eliminate normal surgical scars. To date however, despite an inordinate 
amount of research, there remains no universal or definitive scar treatment 
product or regime. Several newer therapies such as TGF-β initially showed 
promise in small trials but larger trails with extended follow-up regimes failed 
to show the benefit of these treatments 171.  
Similarly the extensive lack of well-conducted, large, randomised controlled 
trials within the literature is striking. Future research must not only seek to 
clarify unanswered questions regarding the safety and efficacy of existing 
treatments but also strive to conduct research on new developments in a 
fastidious fashion. There exists a real need to conduct such studies as 100 
million people in the developed world acquire new scars every year, estimates 
suggest that approximately 11 million of these are keloid scars and 4 million 
are as the results of a burn injury 3,175. Those affected by such scarring are 
known to suffer physical, aesthetic, and psychosocial consequences that may 
be profound 88. Aside from the personal impact of scarring a large financial 
burden is clearly associated for the health sectors, although no official figures 
are available in relation to this.  
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The Holy Grail of scar therapy is yet to be developed but as Bayat et al 
suggest “Future drug treatments hold the promise of substantially improving 
the cosmetic outcome of injury, trauma, or elective surgery, with scarring no 
longer being an inevitable consequence of skin healing” 3.  
Insulin: Mechanism of Action & Scarring 
 
 
Multiple signalling pathways and complex cascades of phosphorylation 
mediate insulin’s physiological actions, the exact nature of which are still not 
fully understood and are beyond the scope of this thesis to discuss in depth 
176. However the main actions of insulin and its signalling pathways will be 
described.  
Insulin is the most potent anabolic hormone yet identified, its primary 
physiological functions are to regulate glucose homeostasis, 
carbohydrate/lipid metabolism, and protein synthesis, it is also fundamental in 
promoting healthy tissue development; as such insulin is essential for life 177. 
Deficiencies of insulin (be that absolute deficiency or a relative insulin 
resistance) results in diabetes where those affected are unable to regulate 
their blood glucose and exhibit abnormal inflammatory responses 177,178. 
Insulin is secreted by the β-islet cells of the pancreas in response to rising 
blood glucose levels, it acts to decrease these levels by promoting cellular 
uptake, reducing gluconeogenesis, and also increases lipid synthesis 177,179. 
In muscle and adipose tissues circulating glucose is dependent on insulin-
stimulated translocation of the glucose transporter GLUT4 to the cell 
membrane 177. The diverse and complex physiological actions of insulin are 
mediated by binding to its specific cellular receptor (Figure 9) 178. 
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Figure 9: Diagram showing some of the main known interactions occurring following the 
binding of insulin to its receptor on the cell membrane. Note the complex molecular cascade 
with pathways to transduce the initial signal and to induce gene expression in response to 
insulin, both of which act to regulate metabolism. Much remains to be deduced about the 
precise nature of these pathways  (Adapted from Zhang) 178 
 
 The insulin receptor is an α2β2-heterotetramer with each subunit performing 
specific functions, the α-subunit forms the insulin binding domain, whilst the β-
subunit is an insulin stimulated (class II) protein tyrosine kinase 180. Thus the 
binding of insulin stimulates tyrosine kinase activity, the two β-subunits allow 
the autophosphorylation of tyrosine residues, which provides the stimulus for 
kinase activation and subsequent binding of downstream insulin signalling 
molecules 178,181. Two isoforms of the insulin receptor are present (A & B) and 
selective insulin signalling via type A and type B receptors differentially 
regulates both insulin and glucokinase gene expression, importantly receptor 
affinity for other ligands appears to differ as well, with type A receptors 
exhibiting a much higher affinity for IGF-II (insulin receptors are homologous 
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to IGF receptors) 178,182. Interestingly this high affinity for IGF-II may well be 
linked to certain cancers in humans, especially breast and colon 183. IGF 
binding proteins have been shown to simulate Smad2 and Smad3 
phosphorylation which may potentiate TGF-β isoforms and influence cell 
growth and inflammation 184, This of course may be of relevance to wound 
healing as well as to carcinogenesis as TGF-β isoforms and Smad3 are 
known to play key roles in the fibroblastic responses in both the fetal and adult 
scar models 185. 
As mentioned above when the insulin receptor is activated it stimulates 
phosphorylation and a number of tyrosine proximal substrates are 
phosphorylated; the so-called “upstream” or “proximal” signalling events. Such 
substrates include the insulin substrate receptor family (IRS’s types 1-4), Shc 
adapter protein isoforms, SIRP’s, Gab-1, Cbl, and APS 177. When these 
substrates are phosphorylated additional recognition sites are created, for 
further effector molecules to act upon which enables the downstream 
signalling events to occur, the most important of which appears to be 1A 
phosphatidylinositol 3-kinase (PI 3-kinase) 177. This molecule appears to be 
essential for the insulin stimulated GLUT4 translocation to occur although the 
specific target(s) of PI 3-kinase are currently unknown (they are most likely to 
be further subclasses of kinases) and additional signals are also required for 
the translocation of GLUT4 177,186,187. The precise upstream signalling that 
actually converge upon the GLUT4-containing vesicles to allow insulin to exert 
its systemic glucose regulating effect is also not currently known 177.  
It can be seen that a great deal remains to be deduced regarding the precise 
actions that insulin (and IGF’s) may have both systemically and locally and 
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even less understood is the precise cascade of molecular interactions that 
mediate it’s effect. Hopefully future research will help to answer some of these 
problems. 
 
Systemic therapy with insulin to maintain tight glycaemic control has long 
been recognised to contribute to wound healing and there is a large amount of 
scientific research confirming this, especially in the diabetic or seriously 
unwell patient with significant wounds 46,47,188–192. The beneficial effect of 
systemic insulin on wound healing is not just limited to traumatic or chronic 
injures, it has been shown that skin graft donor sites heal faster and exhibit 
increased collagen deposition compared to control subjects 191. It has also 
been shown in the literature that wound healing can be significantly impaired 
by elevated systemic or local levels of catecholamines such as epinephrine 
193. Since these chemicals are essentially the physiological opposite of insulin 
(and insulin-like growth factors) it stands to reason that wound healing may be 
expedited in an insulin rich environment. Indeed, In vivo studies have shown 
that Insulin-like Growth Factor (IGF) which is physiologically very similar to 
insulin stimulates the proliferation, migration, as well as matrix excretion by 
fibroblasts, keratinocytes, and endothelial cells 188,194. 
Although most of the literature has concentrated on the effects of systemic 
insulin therapy, a number of studies have examined the application of topical 
or locally placed insulin. In 1968 Lopez treated two cases of resistant 
ulceration of the lower leg, both of which had failed to respond to the normal 
treatment of antibiotics, wound care, and systemic insulin control. He reports 
that the application of local insulin irrigation (30-60 IU insulin daily) resulted in 
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immediate improvement and both ulcers healed completely inside of a month 
195. A more robust study was undertaken by Greenway et al who had noted 
Lopez’s work as well as the improved healing times reported in animals 
models treated with topical insulin but was intrigued by the lack of 
standardisation in these and other reports within the literature 196–198. He 
conducted a randomised, double blind, placebo-controlled trail whereby he 
tested the effect of insulin and zinc upon electively placed forearm incisions 
against placebo. He found that wounds treated topically with insulin healed 
faster 2.4 +/- 0.8 days (p<0.0001) than controls, although he did note that zinc 
was also beneficial in wound healing too 198.  
Zhang et al produced two papers describing the effects of locally injected 
insulin upon wound healing in skin graft donor sites in the rabbit model 199,200. 
They report that in the rabbit model injection of 0.2 IU of long-acting insulin to 
the donor site stimulated wound DNA synthesis compared to donor sites 
injected with zinc preparations and that injection of the donor site with insulin 
every other day expedited healing by 25% compared to placebo 199,200.  
Liu et al showed that insulin not only capable of stimulating keratinocyte 
migration and proliferation but its action is independent of EGF (Epidermal 
Growth Factor) and wounds that have received local insulin treatment have a 
more mature wound epidermis histologically than would be expected. 
Furthermore, the insulin was also found to induce angiogenesis within the 
wound i.e. insulin has potential regenerative qualities 201. The potential for 
insulin/IGF to act in such a regenerative fashion was also suggested by Rolfe 
et al who showed that dermal fibroblasts derived from fetal and post-natal 
humans exhibit different responses to different isoforms of IGF, depending on 
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their maturity, and that it is highly likely that the fetal ability for regeneration as 
opposed to fibrosis is dependent on IGF’s202. 
Whilst a direct connection between scarring and insulin is distinctly absent 
from the literature it is well known that conditions of insulin deficiency e.g. 
diabetes are characterised by excessive fibrosis. Diabetics not infrequently 
suffer with hepatitis, kidney disease, pancreatitis, and lung fibrosis, all of 
which are manifestations of chronic inflammation and fibrotic change 203. As 
one may deduce, if conditions of insulin deficiency promote fibrosis, an 
excess of insulin may decrease this response. Indeed if fibroblasts are 
cultured in a growth factor depleted medium they differentiate into 
myofibroblasts in greater numbers than those cultured in a normal growth 
factor medium. However, the addition of insulin to the growth factor depleted 
medium inhibited this increase in myofibroblasts by up to 80% (in a dose 
dependant fashion) 2. This in vitro experiment was repeated in the mouse 
model where 0.15 IU insulin (Insulatard®) was applied to 1.5cm incisional and 
excisional wounds and the wounds examined. The treated wounds were 
found to have a statistically significant decrease in α-smooth muscle actin 
(SMA), compared to controls, supporting a reduction in myofibroblast 
concentrations 2.  
It should be mentioned in the context of a discussion of the therapeutic 
utilisation of insulin and IGF’s that there is some evidence within the literature 
of an association between insulin and carcinogenesis 204. More specifically it 
is recognised that diabetes is associated with an increased incidence of 
breast (and other cancers) and diabetics who are treated with insulin are more 
likely to develop breast cancer than those using oral hypoglycaemic drugs 
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204,205. The reason for this is likely multifactorial but insulin is a growth factor 
with actions upon cell proliferation via IGF-1. In type II diabetes, patients 
typically exhibit insulin resistance with resultant hyperinsulinaemia and 
increased IGF-1 activity. This may up-regulate cellular proliferation and 
increase the risk of carcinogenesis over a prolonged period 204. Persistent 
hyperinsulinaemia may also increase the levels of bioactive oestrogens, again 
potentially increasing the risk of breast cancer 204. However all studies 
suggesting an increased risk of breast cancer relate to chronic diabetic 
disease with persistent hyperglycaemia and hyperinsulinaemia. There is no 
evidence whatsoever within the literature to suggest any link between either a 
single (very) low dose of insulin or a short course of high dose insulin (e.g. 
patients in intensive care who may require temporary stabilisations of blood 
sugar) and carcinogenesis. 
It can be seen that insulin clearly has premise in the field of wound healing but 
as in many areas surrounding wound healing and scarring there is a definite 
lack of evidence towards demonstrating efficacy (including that of different 
insulin types e.g. short or long acting), dosing regimes, and indeed elucidating 
a reliable mechanism of action within the context of a placebo controlled 
randomised controlled study. Furthermore there appears to be no published 
data that specifically investigates insulin’s effect upon scarring. Most papers 
are directed towards time to wound healing (which in many cases is rather 
arbitrary) or the interactions between fibroblasts, myofibroblasts and insulin or 
other growth factors/cytokines, but fail to assess the scar itself. The scar is the 
final product of wound healing and failure to analyse the properties of this final 
product in the context of the assessment and development of scar treatments 
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needs to be addressed. Baker in his (unpublished) MD project sought to 
address this problem and recruited 15 patients to receive an insulin injection 
(0.3 IU Insulatard®) to the lateral 3cm of the sub-mammary incision in women 
undergoing breast reduction surgery 1. These patients were then followed-up 
and their scars assessed using the Manchester scar scale. Unfortunately the 
relatively low numbers of trial participants did not generate sufficient power to 
allow statistically significant results to be generated, however marked 
differences were anecdotally noted between the treated and untreated scar 1. 
Given the findings of both Baker and Mackie, it was felt that further 
investigation of the antiscarring properties of insulin was merited and this 
forms the basis of the trial design in this study and thesis.  
This study will test the efficacy of a single 0.4 I.U dose of subcutaneous 
insulin to reduce scarring. The 0.4 I.U dose was calculated on the basis of 
previous experimental findings from both in vitro and in vivo studies using 
insulin 1,2. The primary in vitro research centered on insulin’s inhibitory effect 
upon myofibroblasts.  Many cells strains from different individuals were 
assayed for to assess insulin’s inhibitory effects at varying doses. It was found 
that insulin’s efficacy increased with the dose applied until a plateau was 
reached, after which no further inhibitory effect was noted with increasing 
dosages 2.  These findings were extrapolated to the first in vitro mouse 
experiments where 0.15 I.U was injected into a 1.5cm wound (0.1 I.U per cm), 
this was a value taken from the “mid-plateau” range from the in vivo studies 2. 
The dose was considered suitable both by the evidence gained from the in 
vivo studies but also considering the desire to minimise any systemic insulin 
effects. Indeed no demonstrable systemic effects were observed in the study 
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animals 2. Given that 0.15 I.U was used in a 1.5cm wound it was calculated 
that 0.3 I.U should be administered to the 3cm wound under study in the first 
human trial i.e. each centimeter of wound would receive 0.1 I.U insulin-the 
same as the mouse model 1. Clearly if 0.15 I.U insulin demonstrated no 
systemic effects in a mouse it was thought unlikely that 0.3 I.U would effect a 
human with a much greater mass, indeed this was found to be the case with 
no systemic effects observed within the study group 1. Finally for the purposes 
of this phase 2 study a slight dosage increase to 0.4 I.U insulin was decided 
upon. The slight increase in dosage to 0.4 I.U chosen for this study was 
simply a logistic change to do with simplifying the dilution of the insulin for the 
nursing staff involved (see insulin dilution sop appendage). This dose is still 
within the maximum efficacy range plateau determined from the original in 
vivo study and in-fact even 10x that dose would still have been in this plateau 
range 2. As it is such a slight dosage increase (to 4 I.U) it was again thought 
to be extremely unlikely to have any systemic impact and as such was 
implemented for this study.  
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METHODS 
 
Trial Design 
 
The trial was set up to test the efficacy of a proposed anti-scarring therapy, 
which consists of a single low-dose application of insulin applied shortly after 
wounding. It is hoped that the results from this study will establish a new 
therapeutic use for this drug. The trial examines if insulin is effective at 
improving the appearance of post-operative scarring in patients undergoing 
elective bilateral breast surgery. It differs from the previously conducted trial 
assessing insulin as an antiscarring agent in breast reduction surgery in that 
greater numbers of patients have been recruited to increase the studies 
power, the recruited group includes any elective bilateral breast surgeries, 
such as breast reductions, mastopexies, and augmentations. Also differing 
from the previous study the insulin has been applied to the medial aspect of 
the scar as opposed to laterally.  
 
This trial has been performed in accordance with the principals of the World 
Medical Association Declaration of Helsinki and ICH Good Clinical Practice 
(GCP). Ethical approval for this project was obtained from the South East 
Research Ethics Committee (REC reference 10/H1102/67). 
Identification of Patients 
 
Patients were recruited from the Plastic Surgery Outpatient clinics across two 
hospital sites – The Queen Victoria Hospital and McIndoe Surgical Centre 
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East Grinstead. Patients were recruited from those booked to undergo non-
cancer related bilateral breast surgery and meet the following criteria- 
 Inclusion criterion – 
1. Patients undergoing non-cancer related breast surgery. 
 Exclusion criteria – 
1. Patients with diagnosed breast cancer. 
2. Patients with a history (either individual or familial) of keloid 
scarring. 
3. Patients younger than 18 or older than 60 as the rate of wound 
healing is known to be different within these two age groups. 
4. Patients who are currant smokers as smoking impairs wound 
healing. 
5. Patients who have any systemic illness that could have a theoretical 
interaction with the insulin administered such as diabetics, patients 
with renal or liver disease or endocrine tumours. 
 
The exclusion criteria 2-4 are intended to eliminate extra variables that may 
complicate analysis of results.  
Randomisation Process 
 
All patients were treated with both insulin and placebo i.e. an intra-patient 
controlled trial involving two similar wounds on the same patient. It was simply 
which wound received insulin and which received placebo that was 
randomised for each patient. Syringes were labelled right breast or left breast, 
which syringe contained Insulin and which was placebo were randomised. 
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Paired sealed envelopes were prepared that had identical content and were 
fixed to each other. Each pair contained one of the two treatment regimens 
described (Insulin - left breast, placebo - right breast, OR insulin - right breast 
and placebo - left breast).  A pair of sealed envelope that contained identical 
treatment regimens were randomly and blindly allocated to each patient by 
the sponsor of the study, the company Pharmecosse.  
Insulin & Placebo Preparation 
 
Insulin and the control solution were prepared by designated, trained, 
independent clinical operators who were not further involved in the trial. The 
designated clinical operator followed the trial Standard Operating Procedure 
(SOP)  (Appendix 1) to produce a 1ml syringe containing 0.4IU of insulin and 
another 1ml syringe containing diluent only (placebo). These syringes were 
labelled left and right according to the randomisation envelopes instructions. 
The envelopes were then re-sealed and annotated with the patient’s details 
before placing in the clinical trial file. Neither the surgeon, surgical research 
fellow, nor the participant knew which breast received which solution.  
 
Syringes were allocated to each patient, according to the randomly selected 
sealed envelopes containing the treatment regime. The surgical research 
fellow injected the syringe contents as per syringe labelling within the dermis 
of the medial 3cm of incision following suturing. To reduce variables, the 
surgical research fellow performed all suturing. The envelopes were opened 
and details checked with their corresponding envelopes in the clinical trial file 
only once all the wound/scar data has been collected, assessed and 
quantified. 
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Surgery and recovery proceeded as normal, with the only alteration to the 
normal practice being the application of a single subcutaneous injection of a 
low dose of insulin (0.4 IU of Insulatard in 1 ml volume) as described, along 
the margins of the medial 3 cm of the wound under one breast according to 
the study SOP (Appendix 2). The other breast received treatment with 1 ml 
volume of the vehicle only (placebo) control. 
 The dose and formulation of insulin chosen for this study have been 
optimised in the in vitro human and mouse cell models, as well as in animal 
studies, and is similar to that used in the preceding pilot study clinical trials 1,2. 
As patients were randomly allocated to one of two groups (insulin right breast, 
placebo left; or insulin left breast, placebo right), each patient acted as their 
own control.  
Patient Follow-Up & Scar Assessment  
  
Patients were routinely seen again in a dressing clinic for wound inspection 
and/or removal of sutures between 1-3 weeks post-operatively. The surgical 
research fellow attended these appointments to examine and grade the 
wounds visually using the Manchester scar scale (Appendix 3).  The wounds 
were photographed in a standardised fashion according to the study SOP 
(Appendix 4). All photographs were taken using a single hand-held DSLR 
(Cannon® EOS 1000D) under standardised lighting using 4 x 28 watt bulbs in 
a room without natural light next to a labelled standard with scale, in 
centimetres and millimetres, for reference (Figure 10). The standards were 
labelled with scale in order that the medial 3cm of scar could be identified with 
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ease for the purpose of scar analysis and for each photograph the 0cm 
marker was aligned accurately with the beginning of the scar. 
 
Figure 10: The right and left breast scar standards used for reference for photography during 
the trial. All trial subjects’ scars were photographed using these standards to rate insulin 
versus placebo. 
 
The patients’ scars were reviewed again at 3 months, 6 months, and 12 
months following their surgery when they were photographed and the 
Manchester scar score calculated (Figure 11).  
 
Figure 11: Flow diagram illustrating the movement of subjects though the trial and the study 
protocol at each visit.  
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At these visits scar moulds were also taken using the Exafast® NDS system 
from the medial 3cm of treated scars. Exafast is a fast setting vinyl 
polysiloxane which is most commonly used by dentists to take impressions of 
the teeth and gum line. It is applied (and mixed) from a small duel chambered 
cartridge gun in a liquid gel that settles into contours and crevices. Upon 
contact with body heat the mixed liquid sets rapidly and can be easily 
painlessly removed producing a negative moulded model that can be used for 
measurement.   The scar moulds are proposed to be used to estimate scar 
volume using inverse mould volumetric analysis and a 3D imaging system 
using stereo photogrammetry, especially in any cases of extreme hypertrophic 
or keloid scarring. 
Statistical Analysis Recommendations   
 
Independent statistical advice has been obtained from Dr Stephanie Goubet, 
medical statistician at Brighton medical school who advised- 
 
 
• Sample size: In order to detect a difference of 4 units in MSS 
scores (SD=5.1) at alpha=0.05 with 90% power, 36 patients are 
needed in the study. 
• Inter-rater variability: The Manchester scores can be compared 
between the assessors using the Shapiro-Wilks test to account for 
any inter-rater variation. 
• Statistical analysis: Manchester scores can be compared using t-
tests. 
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Study Drug Supply 
 
Both Insulatard and diluent are manufactured by Novo Nordisk® A/S, 
Denmark, and were supplied by Novo Nordisk® Ltd (West Sussex) to the 
Queen Victoria Hospital pharmacy which dispensed for all patients in the 
study irrespective of whether the surgery was performed at the McIndoe 
Surgical Centre or Queen Victoria Hospital. Packaging and labelling was 
according to the labelling requirements specified in the European Commission 
document, Volume 4, Good Manufacturing Practices, Annex 13, Manufacture 
of Investigational Medicinal Products. Both insulin and its diluent were 
dispensed by the pharmacy to the Surgical Research Fellow for each patient 
on the day of surgical procedure.  Insulin and the diluent (control solution) 
were prepared by designated independent clinical operators (theatre nurses) 
who were not further involved in the trial. Each syringe was labelled as either 
right or left as appropriate along with the following details: the title of the trial, 
designated operator name, date of preparation/use, batch number, expiry 
date. These details were entered into the operation record, patient notes and 
the clinical trial file. Accountability was documented in the required fashion 
using a Pharmacy IMP information pack which included an inventory log, 
dispensing log and drug destruction log together with information on insulin 
and its diluent, a reconstitution SOP, shipment details and re-ordering details. 
Histological Analysis of Excised Scar Tissue 
 
A single trial participant (for reasons unconnected with the study) underwent 
revisional surgery, which involved the excision of her pre-existing scars that 
had been treated with insulin and placebo. These scars were excised; labelled 
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left and right respectively, and with the patients consent, immediately 
transported to the laboratory for freezing and processing for histological 
analysis (Appendix 5). The scar tissue was processed for frozen section 
analysis and stained with Haematoxylin & Eosin and Picosirius Red stains 
(Appendix 6 & 7), and underwent immunohistochemical staining with an 
antibody directed against α−smooth muscle actin antibody (Appendix 8). The 
sections were analysed and photographed using the ZEISS® Axio Scope.A1 
microscope and camera. 
Development of Alternate Scar Colour Assessment 
Systems 
 
In addition to recording the standard Manchester parameters, an attempt to 
more accurately quantify the colour of the scars from digital photographs will 
be developed.  
 
ColourWorker®  Scar Colour Analysis 
Spectrometer analysis has been used on a subset of 6 trial participants to 
attempt to provide reference spectra of skin colour for the ColourWorker® 
software to use in its calibration. Calibration spectra were taken from a 
distance of 5mm away from the skin and 2cm away from the scars using an 
Ocean Optics® S-2000 spectrometer. The spectrometer probe is a handheld 
device allowing it to be accurately placed above the area to be assessed. The 
skin lying 2cm away from the scar was measured with a ruler and the probe 
placed in position. Measurements were then recorded. In an attempt to 
standardise the collection of spectral data the recordings were all taken with 
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the participant in the same position and under the same lighting as that used 
for the insulin scar assessment photography SOP (Appendix 4) 
 
Attempts to quantify the scar colour from digital photographs using 
ColourWorker® necessitated the use of Gretag-Macbeth photographic 
standard colour panels (Figure 6). The colour patches on this standard are 
designed to represent a range of encountered skin colours ranging from 
lighter to darker skin types (Fitzpatrick types I-VI). They were placed adjacent 
to the scars during photography to allow colour comparison (to a known 
standard).  
 
The digital images from 44 standardised trial photographs were uploaded on 
to a company computer by a technician and their RGB signals were detected 
and automatically analysed by the ColourWorker® software, utilising the 
photographic colour standard (Figure 12). The software output is of a colour 
evaluation curve that can be interpreted. 
 
Figure 12:  A photograph (left image) is taken with the colour standard and reference is taken 
from this (red line) and from the scar (yellow line). The ColourWorker® software automatically 
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generates contour lines at 0.5mm intervals (middle image) from the known size of the colour 
standard. The software then calculates the pixel RGB values at 1mm intervals along these 
lines. 
 
 
The aim is to see if ColourWorker® software can combine a calibration 
procedure with reference information (from the colour standard and reference 
spectra) in order to measure scar colour from ordinary clinical photographs. 
The ColourWorker® algorithm is used to estimate the spectral reflectance 
(Rλ) or Lab values from the RBG signal. The estimate derives from a linear 
model (fL) relating to a point in a colour space (Rλ1 or Lab) to given points in a 
camera space (RGBC) where the parameters are estimated by: Rλ = 
fL(RGBC).  
The reference biasing and calibration are also estimated by the 
ColourWorker®, through regression of a set of known reflectance spectra, of 
human skin, (RREF) onto a set of predictive camera device response values 
(RGBREF) to these known spectra. Utilising this data ColourWorker® software 
can produce an evaluation curve of the difference of the scar colour to the 
surrounding skin (Figure 13) 
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Figure 13: A scar evaluation curve using ColourWorker®: a quantitative analysis of the 
difference in colour (ΔLab) of a scar and surrounding skin. Note how lightness and colour 
change with distance from the centre of the scar towards normal skin. 
 
Eykona®  Device Scar Colour Analysis 
 
Further colour analysis was conducted on 43 scars within the study group, 
both the scar and the surrounding skin were analysed using the 3D Eykona® 
Wound Measurement System (Figure 12). This device was originally 
developed to assess chronic wounds such as diabetic foot ulcers so that the 
treating clinician may gauge treatment response in terms of changes in wound 
size and shape etc however it was felt that it may have a use in the analysis 
of scar colour. The device is essentially composed of three separate 
components: Camera, standardisation target, and software. There are two 
camera lenses set apart, that act in stereo to produce a 3-dimentional image. 
These stereo cameras combine two sensors to capture the image and four 
independent flash units (Figure 14). The advantage of this system is that 
unlike many 3D units it is easily portable and does not require calibration or 
external static rigs. Also the device records colour in a standardised fashion 
regardless of the lighting in the environment e.g. the picture of any given 
objects colour will be recoded in an identical fashion, whether the image is 
taken in a completely darkened room or in bright sunlight. This feature makes 
the device particularly suited to the recording of colour in a standardised 
fashion. 
The device was used to take a picture of scars in line with the studies 
photography SOP. The scar area was then outlined on the digital image on-
screen with a mouse and the RGB signal images were analysed (Figure 15). 
RGB signals within the outlined area were analysed using a previously 
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validated ICC colour profile incorporated within the device by Eykona® 
technicians to allow conversion the Lab colour coordinates. Specifically 
images were analysed of the treated (by insulin or placebo) 3cm of scar and 
3cm of adjacent skin at a distance of 2cm below the scar (Figure 15).  
 
Figure 14: The Eyknoa® 3D camera device. Note the 2 spaced lenses in the central aspect of 
the camera and the 4 flashes in each corner. Image courtesy of Eyknoa®. 
 
  
Figure 15: 3D reconstructed model using Eyknoa® software. Image shows how colour 
samples are collected. On the left a sub-mammary scar of a participant’s right breast (note 
the Eyknoa® target used to standardise images). On the right, 3cm linear measurements of 
scar and adjacent skin. The device calculates the average colour of these sampled regions. 
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A colour difference value was calculated for each scar and its surrounding 
skin using the standard formula for Lab colour difference (inputted into the 
devices algorithm by Eykona®): 
 
 
 
The scars were also assessed for colour, as per the study protocol, by the 
Manchester scar scale into categories of “perfect match”, “slight mismatch”, 
“obvious mismatch”, and “gross mismatch”, in comparison to the surrounding 
skin. The values recorded by this method were analysed using a Mann-
Whitney U test to deduce statistical differences between the Manchester scar 
scale colour groups. 
Trial Endpoints  
 
The primary endpoint comprises of an assessment of standardised 
photographs of drug and placebo-treated scars. The photographs will be 
assessed by image analysis and panel assessment.  A panel of independent 
experts will assess the scars by modified Manchester scar scale alongside an 
intra-patient scar comparison scale. 
Secondary endpoints included the development of clinically useful adjuncts to 
objectively analyse scar colour from digital photographs to aid quantitative 
evaluation of scars alongside established scar assessment scales. 
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RESULTS 
 
Insulin Study Results 
 
Recruitment: 90 participants (88 female and 2 male) in total were 
recruited to this study over a 2-year period and were followed-up as per the 
protocol. In the entire cohort there were no serious adverse events or 
complications. A single participant developed a minor local allergic type rash 
to the area analysed using the silicone mould but there were no incidences of 
allergy or anaphylaxis to the insulin or placebo. A single participant was 
forced to withdraw as they required further surgery that involved excision of 
the treated scars, although this was entirely unrelated to the trial and not due 
to any scar or wound related problems. The remainder of the trail participants 
were followed-up as per the study protocol with individual scar scale 
assessments, photographic documentation, and silicone scar moulding. All 
data at the point of collection was sent to the sponsor for holding. At no point 
was the integrity of the randomised, blinded nature of the study compromised. 
 
Data Analysis Difficulties: Despite the successful recruitment of 90 
patients to this study, of whom, 37 had completed their 12-month follow-up 
with collection of scar scores and photographic records, a full data set was not 
available for analysis at the time of writing. The study sponsor Pharmecosse 
held all of the raw trial data relating to the insulin study until they issued the 
un-blinding codes as per the study protocol. Unfortunately the sponsor was 
unwilling to release all of the gathered data before the entire cohort (90 
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patients) had completed their 12-month final review (Figure 16). Nor were the 
sponsors willing to unlock the blinding code, least the integrity of the blinded 
nature of the study be compromised. Instead an “interim data analysis” 
consisting of a limited review of the 37 patients was permitted. 
 
Figure 16: CONSORT diagram showing the movement of subjects through the trial, including 
the number recruited and the total number who had completed the final 12-month follow-up at 
the time of writing.  
 
The sponsor approved interim review also however did not permit the un-
blinding of data within this cohort either, nor was full data release permitted. It 
was agree that it would be allowed that the photographic records from these 
patients final review would be presented to a panel of 15 consultant plastics 
surgeons for analysis in the form of a modified Manchester Scar Score, 
including visual analogue score (as per the methods). Since un-blinding was 
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not permitted treatment regimes of insulin or placebo were referred to as 
either “treatment A” or “treatment B”.  Also no data at all was released 
pertaining to the scar scores recorded during the duration of this study. It was 
also stated by the sponsor that the raw data gained from the expert panel 
review for the interim analysis be conducted by a company statistician, who 
had no further involvement with the study. The sponsor was unwilling to allow 
the alternate analysis as had been proposed in the study methods. 
Also omitted from the analysis was information pertaining to the scar 
moulds taken at each participant visit. On review of these moulds no useable 
or analysable data was gained. None of the moulds showed definite evidence 
of a scar line that could be analysed and most moulds were simply devoid of 
feature. As such no attempts were made to analyse scar height or bulk with 
3D studies. 
 
Interim Analysis:  The interim data analysis consisted initially of 37 
participants who had successfully completed their 12-month review. However 
this number was reduced to 36 as one of the photographs was felt by the 
sponsor to be unrepresentative. Scar photographs from the treated area of 
the 36 scars were presented side-by-side in a continuous spread-sheet 
printed on a high-resolution printer to the expert panel. The photographs were 
organised side-by-side into those that had received treatment A or B. The 
panel were asked to complete a modified Manchester scar score, modified as 
the “texture” component of the scale was omitted (as analysis was purely 
visual), upon each of these 36-paired images (Appendix 10). This assessment 
also included completing an intra-patient comparative visual analogue scale 
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(VAS score) between the images (Figure 17). The VAS is also modified as the 
VAS was comparative between the 2 scars i.e. each scar did not have its own 
VAS calculated, as per the original Manchester score. The panel were 
convened on the same day in a single well-lit room to rate the scars. They 
were provided with A4 sheets for each of the 36 patients scars consisting of 
the side-by-side scar photos, VAS, and modified Manchester scar scores as 
per Appendix 10. The photos were printed on a high-resolution printer by the 
medical photographic department at Queen Victoria Hospital. All of the scars 
were rated at the same time and no discussion was allowed between the 
raters until the sheets had been collected. Data from these sheets was then 
analysed. 
 
 
 
Figure 17: An example of the intra-patient comparative VAS. The rater is required to mark the 
point on the scale (arrow), which they believe represents the relative difference between the 
scars  
 
The VAS scores are used by the raters to compare the scars of a participant 
in a quantitative manner. If the rater believes there to be no difference 
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between the scars the scale will be marked in the middle i.e. 0% difference in 
scar appearance, similarly if the rater believes one scar e.g. scar “B” to be 
50% better than scar “A” then the scale will be marked at 50% under 
photograph “B” (Figure 14). Thus any given VAS will be recorded as a positive 
value if it related to treatment A and negative if it responds to treatment B. 
Data were recorded for these VAS scores and the modified Manchester 
scores. Demographic data including age, BMI, skin type, smoking status, 
allergies, and the suture material used to close the wound were also recoded. 
The photographic data presented to the panel for assessment is shown below 
(Figure 18, images 1-36)  
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Figure 18: The right and left sub-mammary 12-month scar photos from the 36 participants 
presented to the expert panel for grading   
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Statistical Analysis of Insulin Data 
 
Demographic Variable Responded 
better to 
treatment A 
(mean VAS>0) 
(n=13)  
 
Median (IQR) 
Responded 
better to 
treatment B 
(mean VAS<0) 
(n=23)  
 
Median (IQR) 
Logistic 
Regression (best 
treatment 
demographic 
variable) 
 
Odds ratio 
 
 
 
 
p-value 
Age (years) 40.00 (28.00, 
51.00) 
40.00 (31.00, 
44.00) 
0.99 (0.94, 1.05) 0.769 
BMI 28.00 (21.00, 
30.00) 
23.00 (21.50, 
26.00) 
0.91 (0.78, 1.04) 0.173 
Timing 1st wound 
check (days) 
12.00 (10.00, 
14.00) 
12.00 (8.00, 
17.00) 
1.07 (0.92, 1.28) 0.382 
Fitzpatrick 
classification 
3.00 (2.00, 
3.00) 
2.00 (2.00, 3.00) 1.15 (0.55, 2.73) 0.723 
 Proportion 
(SE) 
Proportion (SE) Odds ratio p-
value 
Non-smoker (vs Ex-
smoker) 
0.92 (0.07) 0.74 (0.09) 0.24 (0.01, 1.64) 0.207 
Hormone treatment 0.31 (0.13) 0.35 (0.10) 1.20 (0.29, 5.56) 0.806 
Problems at 1st wound 
check 
0.92 (0.07) 1.00 (0.00) 3.00e+07 (0.00, 
NA) 
0.994 
Allergies:     
    Elastoplast 0.00 (0.00) 0.09 (0.06) NA (NA, NA) NA 
    Antibiotics 0.00 (0.00) 0.04 (0.04) 1.00 (0.00, 
2.66e+137) 
1.00 
    None 1.00 (0.00) 0.83 (0.08) 0.00 (NA, 
9.26e+182) 
0.995 
    Pethidine 0.00 (0.00) 0.04 (0.04) 1.00 (0.00, 0.00) 1.00 
Surgery type     
    BBA 0.38 (0.13) 0.52 (0.10) NA (NA, NA) NA 
    BBR 0.38 (0.13) 0.26 (0.09) 0.50 (0.10, 2.44) 0.39 
    Gynaecomastia 0.00 (0.00) 0.04 (0.04) 1.77e+07 (0.00, 
NA) 
0.997 
    Mastopexy/Augment 0.08 (0.07) 0.13 (0.07) 1.25 (0.12, 28.72) 0.861 
    Mastopexy 0.15 (0.10) 0.00 (0.00) 0.00 (NA, 
1.37e+182) 
0.995 
    Revision 
Mastopexy/augment 
0.00 (0.00) 0.04 (0.04) 1.77e+07 (0.00, 
NA) 
0.997 
Suture material     
    Monocryl 0.77 (0.12) 0.87 (0.07) NA (NA, NA) NA 
    PDS 0.00 (0.00) 0.04 (0.04) 7.83e+06 (0.00, 
NA) 
0.995 
    Rapide 0.23 (0.12) 0.09 (0.06) 0.33 (0.04, 2.32) 0.268 
 
 
Figure 19: Summary table of collected data points and relative score for those in receipt of 
treatment A and treatment B 
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Outcome variable Shapiro-Wilkes test for normality p-value 
Mean VAS. A 0.115 
Mean colour. A 0.403 
Mean Appearance. A <0.001 
Mean contour. A 0.005 
Mean distortion. A 0.009 
Mean total. A 0.118 
Mean colour. B 0.163 
Mean Appearance. B <0.001 
Mean contour. B <0.001 
Mean distortion. B  0.007 
Mean total. B 0.011 
 
Figure 20: Shapiro-Wilks test for normality in relation to the outcome variables (p <0.05 shows 
data is not normally distributed). Outcome variables marked “A” or “B” signal the score 
associated with the image which received treatment A or B respectably. (n= 36)  
 
Outcome 
variable 
Treatment 
group A 
Treatment 
group B 
p-value Effect size (95% 
CI) 
Mean total 6.2 6.34 0.962 0.03 (-0.6, 0.43) 
Mean colour 2.16 2.19 0.974 0.00 (-0.23, 0.23) 
Mean appearance 1.11 1.15 0.133 -0.07 (-0.13, 0.03) 
Mean contour 1.42 1.45 0.574 -0.03 (-0.20, 0.13) 
Mean distortion 1.51 1.55 0.850 0.00 (-0.17, 0.13) 
Mean VAS NA NA 0.900 0.61 (-9.31, 10.45) 
 
Figure 21: Group comparisons between the entire cohort (n= 36) using paired sample 
Wilcoxon signed rank for the Manchester score and t-test for VAS.   
 
From the cohort of 36 trail participants in the interim data review 6 individuals 
affected by heavier scarring were analysed as a separate subgroup. It was 
taken heavier scarring was that represented by a documented score of >2 
points relating to their worst scar contour on the Manchester scar scale 
(Figure 22).  
Outcome 
variable 
Treatment 
group A 
Treatment 
group B 
p-value Effect size (95% 
CI) 
Mean total 6.38 8.57 0.036 -2.07 (-2.87, -1.67) 
    Mean colour 2.08 2.90 0.036 -0.83 (-1.20, -0.33) 
    Mean 
appearance 
1.19 1.43 0.036 -0.23 (-0.33, -0.17) 
    Mean contour 1.54 2.19 0.035 -0.57 (-0.90, -0.20) 
    Mean distortion 1.57 2.04 0.036 -0.47 (-0.77, -0.20) 
Mean VAS NA NA 0.006 37.51 (16.42, 
58.59) 
 
Figure 22: Group (n=6) comparisons between the cohort with more severe scarring using 
paired sample Wilcoxon signed rank for the Manchester score and t-test for VAS. 
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Interpretation of Insulin Data 
 
 Sensitivity Analysis Of The Groups As Defined By Their Response 
To Treatment: Trail subjects were classified as responding to treatment A if 
their mean VAS scores were greater than 0, if the mean VAS was less than 0 
they were classified as responding to treatment B. From the cohort of 36 
subjects 23 responded to treatment B compared with 13 who responded to 
treatment A. 
There were no substantial differences between the two treatment groups in 
terms of subject demographics. Although those who responded to treatment B 
had a slightly lower BMI (median BMI in kg/m2 (inter quartile range {IQR}) = 
23.00 (21.00, 26.00) versus 28.00 (21.00, 30.00) for the group that responded 
to treatment A. There were a slightly lower proportion of non-smokers versus 
ex-smokers (proportion (standard error {SE}) = 0.74 {0.09} for subjects 
responding better to treatment B versus 0.92 {0.07} for those responding to 
treatment A. Finally there was a higher proportion of people with allergies (of 
any kind), 4 out of 23 who responded to treatment B had an allergy compared 
to 0 out of 13 who responded to treatment A. 
There were no differences at all noted between group A and B in terms of 
age, Fitzpatrick skin type, hormone therapy, suture material, timing of wound 
check, or problems affecting the injected area. The number of categories of 
surgery type was too many to suggest any possible treatment responses 
within the sample size. 
 Normality Analysis: The mean VAS and the mean Manchester scores 
(in all categories) were normally distributed between the A and B groups as 
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per the Shapiro-Wilks test (Figure 20). All other variables did not meet the 
conditions for normality. 
 Comparison Between The Groups Within The Entire Cohort: The 
mean VAS score was not significantly higher or lower than 0 (mean VAS 
score = 0.61, 95% CI = {-9.31, 10.54}, one-side t-test p-value = 0.900, two-
tailed. Paired sample Wilcoxon signed rank tests were used to compare 
Manchester scores from the two groups. There was no significant difference 
between them, nor between the individual Manchester score components 
(Figure 21). 
 Analysis Of The Group With Severe Scarring: Score analysis of the 
6 subjects affected with heavier scarring (as defined by their worst 
Manchester contour score being greater than 2) all showed a mean VAS of 
more than 0, that is they responded to treatment A upon analysis (mean VAS 
= 37.505, 95% CI = {16.42, 58.59}, one sided t-test p-value = 0.06, two tailed).  
The paired Wilcoxon signed ranks of this cohort show better response 
(treatment effect) to treatment A compared to B of 2.07 (95% CI 1.67, 2.87) p-
value = 0.036 (Figure 22) 
 
Insulin Study Discussion 
 
Was The Trial Design Appropriate To Meet The Objectives? This 
trail was designed to assess the efficacy of insulin as an anti-scarring agent; 
the scar model chosen was a 3cm section of the sub-mammary incisions in 
bilateral breast surgery. The use of breast scars is indeed appropriate as a 
scarring model. By definition the scars will be symmetrical, placed in identical 
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anatomical regions, and will have been created from a controlled injury at a 
standard depth i.e. surgical incision within a single subject. Furthermore all of 
the wounds included in the study were sutured by the same registrar level 
surgeon (research fellow), which eliminates any technical or procedural bias 
that may have influenced healing and subsequent scarring. All other aspects 
relating to the wound closure such as suture material and dressings were 
identical between within each participants compared scars, though not 
necessarily between trail participant’s i.e. different suture types were used for 
different subjects across the trial according to the consultant surgeon 
preference. The use of the breast scar model eliminated some of the 
variability associated with many other anti-scarring trails where either scars 
were placed in different anatomical areas, scars were compared across 
different individuals, the wounds created in an uncontrolled manner or the 
wounds were sutured by differing individuals 169,206,207. As such it would 
appear that the use of the intra-patient breast scars as a model is effective to 
compare treatment versus placebo within the same subject in a reliable and 
repeatable fashion.  
This trail was placebo controlled allowing for accurate assessment of 
any treatment effect of insulin. The insulin and placebo was administered in a 
fully blinded, randomised fashion allowing completely non-biased assessment 
of resulting scars. Subsequent photographs and Manchester score sheets 
(Appendix 10) were taken for analysis by the expert panel composed of 15 
consultant plastic surgeons based at Queen Victoria Hospital. All analysis was 
completed at the same time, using identical sheets, and with no discussion 
allowed between raters. All panel members involved reported that they felt the 
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assessment and comparison of scars was easily achieved through the 
photographic representation and layout, again suggesting an appropriate and 
successful study model.  
The follow-up protocol necessitated a wound check within 2 weeks and 
subsequent follow-up visits with scar scoring and photography at 3, 6, and 12-
months. The wound check element of the follow-up protocol was successful 
and appropriate in that it allowed for early assessment of participants 
following intervention i.e. potential problems associated with the trail would 
have been identified. Similarly follow-ups at the 3 and 6-month periods 
allowed for observation of treatment effect over time and provided multiple 
data points for comparison, however due to the data release permitted by the 
sponsor information and photographs relating to these visits were not 
released at the time of writing. The 12-month i.e. final follow-up assessment 
photographs were released for assessment by the expert panel but the scar 
assessment data collected at the time of examination by the surgical research 
fellow was not released.  A potential criticism of the follow-up arrangement 
could be that the final assessment should not be conducted at 12-months as 
the scar may not be fully mature. However most studies show that scars at 
12-months show no evidence of on-going inflammation and is generally 
regarded as the time where a scar has matured, although there are 
references within the literature that suggest the process may last up until 2-
years 12,25,139,208. Despite a small amount of evidence within the published 
literature suggesting scar maturation may not be complete at 12-months it is 
still suggested that this is an appropriate time to assess treatment efficacy. 
Even if the scar has not fully matured any treatment effect should be apparent 
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by this stage and as such certainly allowed assessment appropriate for the 
study aims to be achieved. If treatment effect was to take place in a time scale 
greater than 12-months post application then the marketability and suitability 
of any resulting clinically available product would be severely limited. Most 
patients would not likely invest or be interested in a product that shows no 
effect for over a year in any case, again supporting the use of a final review at 
12-months. It would have been interesting to see if the assessments taken at 
the time of examining by the surgical research fellow matched the findings of 
the expert panel. However even if these results were substantially different 
the observations of 15 experts would carry more power and significance than 
the observation of a single rater and as such any results would likely remain 
for interest only.  
Scar moulds were taken at all visits aside from the wound check in 
order to try and quantify scar bulk and link this to any treatment effect. The 
NDS scar moulding system® used within the study did not achieve its aims. 
No moulds showed any definite scar lines that could be used to determine 
scar bulk from subtractive 3D imaging. This may be of course because none 
of the scars examined were excessively bulky or raised. Also the natural 
curvature of the sub-mammary region may influence the gathering of such 
data. The gel-like nature NDS at the point of application may also have 
contributed to the failure of gathering effective scar moulds. If the gel was too 
viscous it may not have “draped” or “moulded” around a raised scar 
effectively, producing smooth contoured edges where in-fact there was a 
definite raised area. The NDS system is of course not designed for the 
purpose of measuring scar bulk; it is used to take dental impressions. In such 
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cases resultant impressions may not require the level of sensitivity that is 
required to assess a potentially very minimal elevation of a scar. Also the 
system is designed to be used within a tray that is held against the teeth 
and/or gums by the dentist for a period of minutes whilst the solution hardens. 
Holding the mixture against the scar on a rigid construct would not be possible 
or appropriate for the means of this study. Firstly, the application of pressure 
would likely distort the scars and possibly depress then, giving false readings. 
Secondly, it would be very difficult to hold a rigid platform in the area under 
the breast with any degree of control or in a reproducible fashion. Any 
physical measurements and subsequent 3D rendition of images could also 
potentially be inaccurate if the area being examined showed excessive 
curvature in multiple directions (as the sub-mammary area does). As such it is 
suggested that this is not an effective outcome measure to use in scar 
assessments or trails. In theory the technique may haver some limited 
application in extremely bulky hypertrophic or keloid scars, however within the 
context of this trail there is no role for this form of assessment. It may well be 
more effective to image the scars directly with a portable 3D camera that 
could measure the elevation and potential volume of raised scars. 
 Adherence To Trial Protocol: All aspects of the trails protocol were 
followed. The recruited participants all received either insulin or placebo in a 
randomised fashion and were followed-up in accordance with the agreed 
timeframe at wound check, 3-months, 6-months, and 12-months. All 
participant scars were scored and photographs taken at each visit. In addition 
at all visits after the wound check scar moulds were taken from all, aside for a 
single participant who developed a minor reaction to the silicone at the 3-
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month check from whom no further moulds were taken. All data remained 
blinded throughout.   
Recruitment: Recruitment to the study proceeded at a rate slower than 
that was estimated during the trail design phase. It was initially estimated with 
the volume of non-cancer breast surgery occurring over the two hospitals 
(Queen Victoria Hospital and McIndoe Surgical centre) that at least 70 
patients would be recruited in the first year. Recruitment was hampered by the 
fact that elective breast surgeries became had become increasingly fiscally 
rationed by the NHS over recent years. During the 2011 study period there 
was a 55% reduction in aesthetic breast surgeries performed at Queen 
Victoria Hospital compared to 2005 209.  Furthermore many of those 
operations classed as “aesthetic” were in-fact secondary (often symmetrising) 
surgeries following breast cancer reconstruction and as such were ineligible 
for trail inclusion. This significant decrease in suitable surgeries within one of 
the recruiting sites substantially limited the recruitment rate. Furthermore 
recruitment at the NHS site was severely hampered by an unforeseen hurdle; 
many of the patients treated at the hospital were planned in-fact to be 
followed up in other peripheral hospitals post-operatively. Understandably 
potential participants were reluctant to attend follow-ups at two separate 
hospitals, often with considerable distances between them. Recruitment was 
potentially also slower than predicted due to a general consensus amongst 
surgeons that there was a reduction in people paying privately for cosmetic 
surgeries during the financial crisis that coincided with the study, although no 
official figures were available from the McIndoe Surgical centre to substantiate 
this. However despite a slower than predicted rate of recruitment, within a 
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two-year period 90 individuals were successfully entered into the trail and 
aside from 4 individuals all other participants completed, or are on course to 
complete, the planned follow-up schedule. This number of participants is 
larger than a number of similarly designed phase II scar treatment trails and 
represents a very successful process 169,170. 
 
Photography Standardisation & Quality: Photographs were 
standardised as far as was possible outside of a photographic studio. All 
pictures were taken under the same lighting with the same camera and 
camera settings. Participants were photographed on a medical bed with the 
backrest at a measured angle of 30 degrees from both the left and right sides. 
All photographs were assessed for quality being considered as final images. 
In addition every month a conference call was arranged with the studies 
sponsors where the quality of the photography was discussed. It was agreed 
that throughout the study there was only a single scar photograph taken that 
did not reach the standard required for accurate scar analysis. Again this 
represents a significant success of the study and allowed for effective scar 
analysis from the assembled expert panel. 
Whole Group Data Analysis Discussion 
  
The data analysis of 36 patients was just sufficient in terms of (statistical) 
power. Our statistical advice at the point of study design had recommended a 
minimum of 36 patients be recruited to ensure adequate power. This 
indicates, in broad terms at least, that meaningful interpretation of the studies 
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gathered data is possible. Analysis from a panel of 15 experts also adds 
significant weight to the interpretation of the results. 
Importantly it can be seen from the results (Figures 19 & 20) that the 
data was normally distributed in terms of mean VAS scores and across the 
mean analysed components of the Manchester scar scores (colour, 
appearance, contour, distortion, and colour). The mean VAS scores were not 
significantly different between the groups who responded better to treatment 
A or treatment B i.e. there was no substantial deviation away from a mean 
score of 0, suggesting no difference in treatment effect between insulin and 
placebo. Anecdotally however it is suggested that most scars analysed in this 
limited data release appear to show differences between them to this single 
observer and one is curious to see if analysis of the full cohort of 90 recruited 
participants may show a treatment effect (of either treatment A or B) as the 
studies power increases. 
The recruited group was relatively homogenous in terms of 
demographics and responses to treatment. There were no significant 
differences between the groups who responded better to treatment A versus 
treatment B as a cohort. Specifically no differences were noted between 
responses to treatment A or treatment B within the group in respect to age, 
skin type (Fitzpatrick rating), suture material, those taking hormones 
(contraceptive pills of different varieties), timing of initial wound check, or 
problems affecting the operative site. Once again suggesting that there is no 
difference in treatment effect between insulin and placebo. Initial interpretation 
of these results suggests quite convincingly that there was no significant 
difference in treatment response between treatment A or treatment B. Whilst 
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the data is still blinded it can be said that taking the group as a whole it 
appears that insulin has no observable treatment effect since there was no 
difference in mean VAS scores, or indeed between any of the components of 
the Manchester score. 
However some minor demographic variations between the groups were 
noted. Those who responded to treatment B had a slightly lower BMI than 
those responding to treatment A (median 23.00 versus 28.00).  A very small 
proportion of never smokers versus ex-smokers responded more favourably 
to treatment B, and a higher proportion of those with allergies, of any sort (4 
out of 23) responded more favourably to treatment B. It is hard to interpret 
what these data may represent. Logic would suggest that the fact that an 
individual has an allergy should not in any way influence a treatment that 
utilises a drug different to that to what they are allergic to. Indeed no reference 
could be found within the literature suggesting any link between drug allergies 
and efficacy of scar treatments and it would seem very unlikely that any 
treatment effect has been observed in relation to this. Those that admitted to 
having previously smoked but were otherwise fit and physiologically well 
enough to undergo purely elective (often aesthetic) surgery would also 
suggest that this variable should have little to do with treatment effect of either 
insulin or placebo as wound healing, a hence resultant scarring, should not be 
affected. A previous study showed that in patients undergoing breast 
reduction surgery that the incidence of wound complications was greater in 
those that had stopped smoking less than 4 weeks before surgery compared 
to those who had given up for longer periods (56% versus 33%) 210. Whilst our 
study did not specify the duration of smoking cessation within the ex-smokers 
 109 
recruited the study as a whole had a very low rate of wound problems post-
surgery (Figure 19) and in any case there were no differences in wound 
complications between the two groups. The observation relating to the fact 
that those with a slightly lower BMI responded better to treatment B is also of 
uncertain significance. It is known that those with higher BMI’s are more likely 
to have degrees of insulin resistance or type II diabetes which in theory could 
contribute to alterations in treatment effect (of insulin) 211. The median BMI 
was 23.00 in group B and only a modestly higher BMI of 28.00 in group A, 
which would not be considered significantly obese by national 
recommendations and as such individuals would not likely be suffering from 
any insulin resistance that may influence treatment 212.  Also relevant is the 
fact that none of the recruited participants had documented diabetic disease 
(as per study protocol) and as such would be expected to respond on a 
physiological level to insulin in the same fashion. What may be a more 
interesting interpretation of the BMI treatment response data is that those 
patients with an increased BMI are logically much more likely to have been 
undergoing breast reduction surgery than those with a lower BMI. It is well 
known that high wound tension in surgical incisions results in greater scarring 
and those undergoing breast reduction surgery not only have much bigger 
incisions but the wounds are often under significantly greater tensions 
compared to those having breast augmentation 213. If breast reduction surgery 
results in heavier scarring compared to breast augmentation then any 
potential treatment effect may become more apparent i.e. it is easier to 
identify treatment effect in a more dramatic, heavier scar. However this of 
course does not explain why those with a lower BMI responded better to 
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treatment A and remains a casual observation only. Indeed it can be seen that 
there were too many categories of surgery given the number of samples 
within the study to suggest any relationship of treatment effect with surgery 
type (Figure 19).  
Sub-group Data Analysis Discussion: Whilst the trial group as a 
whole showed no particular treatment effect to either treatment it is interesting 
to see that the participants who were classified as suffering with heavy 
scarring responded better to treatment A. Heavy scarring was defined as 
those participants whose worst Manchester scar scale contour rating was >2. 
A score of 3 in this category would indicate a hypertrophic (pathological) scar 
and thus a score of >2 would appear to form a reasonable basis to segregate 
those who are affected by heavy scarring within the cohort, although there 
exists no universally accepted definition of severe scarring within the 
literature. The mean VAS scores within this small cohort (n=6) are all 
significantly higher than 0 (p = 0.006), suggesting a better response to 
treatment A (Figure 22). The Wilcoxon signed rank tests that were used to 
compare the Manchester scores between the two treatment groups suggest 
that all parameters showed a response to treatment A i.e. those in this group 
showed lower total scar scores. The effect size of treatment A compared with 
B showed a reduction of 2.07 (95% CI 1.67, 2.87) p= 0.036, a significant 
response (Figure 22). This treatment effect in those affected with heavy 
scarring shows that treatment A is clinically effective in reducing scarring, 
albeit in a small cohort. Given that the results have shown that other than the 
observation that non-smokers responded slightly better to treatment A (in the 
larger cohort) all other demographic variables would seem constant and the 
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most pertinent difference between the group is the presence of heavy 
scarring. The fact that heavy scars have responded significantly to one 
treatment is interesting. It may be that as was briefly mentioned earlier that in 
those individuals affected with heavy scarring any observable treatment effect 
would be much more apparent. That is to say that if any given treatment 
improves a scars appearance that difference will be very hard to see if the 
control scar has also healed very well. It is again suggested that patients 
undergoing breast reduction are more likely to be afflicted with heavier 
scarring, however the relatively small number within this analysis do not 
permit any confirmation of this suggestion. The results show that treatment A 
may well have application in areas or individuals are expected to suffer heavy 
or pathological scarring. Individuals who may be anticipated to suffer such 
scarring may include those with burn injuries, a previous history of developing 
pathological scars, or is anticipated to have surgery in anatomical areas prone 
to heavy scarring such as the deltoid or pre-sternal regions. It is unfortunate 
that more patients were not included in the data analysis as further data may 
have pointed to specific operations or individuals that would benefit from 
treatment A. Of further frustration is the fact that the results remain blinded 
and it remains at present unknown if treatment A represents the insulin or 
placebo. In the near future when the full dataset is released by the sponsor in 
an unblended fashion hopefully any treatment effect will not only be more 
apparent with the increased power but will also be able to be ascribed to 
either insulin or placebo. In any future similar studies it would likely to be 
helpful to include individuals to the study who actually do have a history of 
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heavy or pathological scarring, unlike in this study where such individuals 
were excluded, to observe any potential treatment effect.  
 
Conclusion of Insulin Study 
 
Evaluating the entire cohort the results show that there is no difference in 
scarring between those in receipt of treatment A or treatment B. However 
examining those affected by heavier scarring within the cohort showed that 
treatment A was effective in reducing the appearance of scars. The group in 
receipt of treatment A showed a statistically significant reduction in their mean 
Manchester scar scores and VAS scores. The results suggest that treatment 
A may have application in the prevention of excessive scarring in those that 
may be prone, such as those with burns or a previous history of heavy 
scarring. Further evaluation of these results will be required when the full 
dataset is released and the un-blinding code is broken.  
 
Histological Results 
 
A single trial participant had to undergo revisional surgery (for reasons 
unconnected with the trial), which involved excising her right and left sub-
mammary scars, and hence she was removed from follow-up. However 
following excision these scars were processed for histological evaluation. 
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Haematoxylin & Eosin Specimens: 
 
Figure 23: H&E (x50). Left breast scar.   Figure 24: H&E (x50). Right breast scar. 
Note the flat dermal junction (double arrow) Multiple rete plugs (arrows) 
And lymphocytic infiltrate (orange arrows) 
 
 
Figure 25: H&E (x200). Left breast scar. A flat Figure 26 H&E (x200). Right breast scar. 
dermal junction under higher magnification.  Rete plugs under higher magnification.  
 
 
 Alpha-Smooth Muscle Actin Specimens: 
 
Figure 27: α-SMA (x200). Left breast scar  Figure 28: α-SMA (x200). Right breast scar 
showing a number of fibroblasts               showing a number of fibroblasts 
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 Picosirius Red Specimens: 
 
Figure 29: PR (x200). Left breast scar under Figure 30: PR (x200). Right breast scar under 
polarised light exhibiting birefringence  polarised light exhibiting birefringence 
 
Discussion of Histological Results 
 
The two scar specimens analysed were taken from the right and left sub-
mammary scars that had previously been treated with insulin and placebo 6-
months prior to their collection. The participant underwent further surgery that 
involved excising these scars and as such she was removed from the trial but 
consent was taken to analyse her scars. Due to the fact that data un-blinding 
has not occurred at the time of writing we do not know which scar was insulin 
treated and which scar received placebo only. However some morphological 
differences could be observed between the two scars. 
The specimens stained with H&E exhibited the most obvious morphological 
differences. Most striking of these was the relative flat, featureless 
appearance of the left dermo-epidermal junction compared with the right 
specimen. The right specimen appeared to have a much closer morphology to 
normal skin with definite rete plugs and ridges producing an undulating 
dermo-epidermal junction. Whilst this was not as pronounced as one would 
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expect to see in unscarred skin it is in marked contrast to the left side where 
little evidence of normal morphology could be seen in the dermo-epidermal 
junction. A more defined system of rete plugs and ridges is one indicator that 
shows that a scar is morphologically more mature. In an observational study 
Fergusson et al noted that scars typically started to develop rete plugs and 
ridges 7-9 months following injury with progressive delineation after this 139.  
Other than the differences between the dermo-epidermal junctions it was 
noted that there appeared to be a greater number of lymphocytic inflammatory 
infiltrate within the left scar. However this is a purely anecdotal observation 
only as no reliable lymphocytic counts were performed as multiple scar 
specimens would have had to been examined to confirm this statistically 
across a large cohort in receipt of either treatment A and treatment B. An 
increased lymphocytic count within a scar is typically seen in more mature 
scars where the maturation process reorganises the collagen architecture as 
the inflammatory response fades. Although as stated no firm conclusions at all 
can be made in relation to a single specimen such as this.  
No discernable difference between the collagens orientation or appearance 
was noted on H&E staining between the scars. Indeed examination of the 
picosirius red specimens under polarised light revealed very little difference 
between the scars. Picosirius red is a selective stain for collagen and can 
differentiate between different collagen types. Type I collagen fibres are 
typically thick, birefringent red or yellow in appearance, whereas type III 
collagen is a weakly birefringent greenish colour 214,215. It can be seen from 
the birefringent red colouration throughout the dermis of both scar specimens 
that there was a large amount of type III collagen present. Little, if any, green 
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type I collagen is visible in either specimen. The large amount of type III 
collagen is probably to be expected in a maturing scar and no observable 
difference could be noted between the two specimens. 
Finally the specimens were also examined using Alpha-smooth muscle actin 
antibody, which is specific for highlighting myofibroblasts. In both specimens it 
can be seen that there are numerous fibroblasts present within the scars, 
which is to be expected, but no antibody positive myofibroblasts were 
observed. It appears that the left scar has a relatively higher density of 
fibroblasts compared to the right. This may suggest that a larger amount of 
collagen or extracellular matrix deposition could potentially occur in this area 
due this higher density, which in theory could contribute to a heavier or more 
scarred appearance. However once again this is a purely anecdotal 
suggestion and no firm conclusions can be made without analysis of multiple 
specimens and formalised cellular measurements performed. 
It can be seen from the limited histological analysis gained from this study that 
there are some observable differences between the two scars, most notably 
the more normal appearance of the dermo-epidermal junction of the left scar 
upon H&E staining. This difference hints at a treatment effect, or certainly 
some accelerated maturity of the right scar. However these results must be 
viewed with caution and no firm conclusions can be made. The results gained 
from the other specimens stained with α-SMA and PR do not reveal any 
significant observable differences that can be interpreted with any degree of 
confidence. The specimens examined represent a single subject only, hence 
no comparisons to other trial participants can be made, nor do we know what 
scar received insulin or placebo. Secondly there is no way of knowing from a 
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single specimen if there were any compounding factors that may have 
influenced that scar such as mechanical stresses or sub-clinical infection etc. 
Such factors could exacerbate an inflammatory response or slow healing 
relative to the contralateral side. Furthermore given that only a single 
participants scars were evaluated no statistical analysis could be performed 
either and as such all results are purely observational in nature and subject to 
error.  
 
Conclusions of Histology Analysis 
 
It appears that tissue examined from the right breast scar exhibited a more 
mature pattern with defined rete ridges and plugs and possibly less 
inflammation when compared to the left breast scar. This suggests that some 
difference may be observable at the histological level of treatment A versus 
treatment B. As discussed previously however the histological analysis was 
very limited in nature, due to the opportunistic nature in its collection, and no 
firm conclusions can be made. Indeed due to the un-blinded nature of the 
data it is impossible to know if the potential treatment effect is due to insulin or 
lack of i.e. placebo. It would be interesting to analyse further insulin treated 
scars in future studies to see if any of these finding were replicated in a 
statistically significant fashion, especially through the use of accurate cell 
(lymphocytic) counts and further morphological studies. 
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Eykona®  Device Results 
 
A total of 43 scars were imaged using the Eykona® device as well as being 
visually assessed for colour as per the Manchester Scar Score and rated as 
either “perfect match”, “slight mismatch”, “obvious mismatch”, or “gross 
mismatch”. In this study there were no “perfect match” classifications. The 
difference in RGB readings between the scar and the adjacent skin were 
calculated and converted to Lab readings. The range of Lab colour difference 
(ΔLab) was calculated for each scar and the mean value calculated (Figure 
31) (Appendix 9) as well as the mean and standard deviation (Figure 32).  
 
 
 
 
Figure 31: Graph showing the difference in Lab readings between scars and adjacent skin for 
Slightly Mismatched (Blue Line), Obviously Mismatched (Red Line), and Grossly Mismatched 
(Green Line) scars  
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 Number of Scars Mean Colour 
Difference (ΔLab) 
Standard Deviation 
(ΔLab) 
Slightly Mismatched 
 
34 10.4 3.9 
Obviously Mismatched 
 
6 13.4 2.3 
Grossly Mismatched 3 19.1 1.00 
 
Figure 32: Subset of scars analysed using the Eykona®. Scars were classified by colour as 
per the Manchester Scar Scale to compare Lab readings across and within groups. 
 
 
 
 
 
Figure 33: Distribution of ΔLab readings within the scar colour classification of the Manchester 
Scar Scale, Slightly Mismatched (SM), Obviously Mismatched (OM), and Grossly Mismatched 
(GM). Adapted from Hallam et al 130.  
 
A one-tailed Mann-Whitney U test revealed a statistically significant difference 
between the ΔLab values for groups classified as slightly and obviously 
mismatched (p<0.025) as well as between obviously and grossly mismatched 
groups (p<0.05) 130. 
ColourWorker®  Results 
 
The collection of reference spectra from the trail participants as per the 
planned methodology was not successful. No reference spectra were 
retrieved from the spectrometer analysis despite multiple attempts. All data 
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captures resulted in excessive specular highlights that prevented the 
collection of any data that could be used as a reference skin spectra for the 
ColourWorker® system.  
A total of 44 scar photographs were put forward for colour analyses using 
ColourWorker® (utilising an alternative reference spectral database). Of these 
images, 35 were rejected for analysis due to excessive specular highlights or 
evidence of uneven illumination. 
The remaining 9 images did not exhibit uneven illumination or specular 
highlights and thus were analysed for colour using the software (Figures 34-
42).   
 
 
Figure 34: Scar 1’s evaluation curve 
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Figure 35: Scar 2’s evaluation curve 
 
 
Figure 36: Scar 3’s evaluation curve 
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Figure 37: Scar 4’s evaluation curve 
 
 
 
Figure 38: Scar 5’s evaluation curve 
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Figure 39: Scar 6’s evaluation curve 
 
 
Figure 40: Scar 7’s evaluation curve 
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Figure 41: Scar 8’s evaluation curve 
 
 
Figure 42: Scar 9’s evaluation curve 
 
Figures 34-42: Sample scar trail photographs next to their scar evaluation curves for the 9 
selected as suitable for evaluation. The estimated scar width and maximal colour difference 
(ΔLab) between scar the line and the normal skin is indicated by the red and green lines 
respectively.  
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Discussion of ColourWorker®  Results 
 
The use of the ColourWorker® software to analyse colour within the sub-
group of trail subjects, comprised two components. Firstly the gathering of 
reference spectra from normal skin and secondly the analysis of scar colour 
compared to the surrounding skin. The second component i.e. accurate colour 
measurement of scars is dependant on the measurement of reference 
spectra. The reference spectra are important because the underlying 
algorithm utilises these reference spectra to make colour calculations. The 
software essentially comprises two stages. Firstly, an estimate is made of the 
model of the camera that has taken the photograph. Models in this context do 
not relate to the make or manufacturer of the camera, rather to the way the 
camera encodes colour i.e. how the device records different wavelengths and 
black/white intensities. All devices are different in this respect and as such this 
variability needs to be accounted for in any quantitative analysis via a 
calibration 216. However this information alone is not sufficient to allow 
accurate colour estimates from a photograph because the RGB signal of the 
image is relatively simple and makes no record of how any given object 
reflects light i.e. its reflectance spectra. Thus the second part of the algorithm 
relies on known reference spectra to account for this variation in reflectance 
and allows the calculation of an accurate colour from the RBG data. If a 
reliable (consistent) set of reference spectra is obtained from the reference 
material, skin in this case, then colour estimation should be accurate 216. 
Figure 43 shows how the reference spectra and calibration are used by the 
software. 
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Figure 43: The ColourWorker system utilises the RGB signal from a digital image and through 
calibration algorithms records an accurate colour of the subject. Diagram devised by John 
Anderson of ColourWorker® 216. 
 
Discussion of gathering reference spectra 
 
As can be seen from the results we did not manage to record any usable 
reference spectra from the participants skin. This was due to the fact that all 
spectra collected showed evidence of excessive specular highlights, distorting 
the underlying reflective spectra (Figure 44). 
 
Figure 44: An example of attempted capture of the skins reference spectra with excessive 
specular highlights making analysis impossible. Note the wide variation in the captured 
wavelengths at both long and short ends of the spectra (arrows) 
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It can be seen in the above figure that the gathered spectra shows extremely 
wide variation in captured wavelengths throughout the spectrum. This wide 
variation in wavelengths, especially at the extremes of the spectrum, is 
inconsistent with expected values and shows the degree of spectoral 
reflectance. One would expect a much narrower variation in wavelength from 
human skin, as other authors have shown (Figure 45) due to the relative 
homogeny of the colour. Spectral readings such as those gathered during this 
study are unreliable, especially if they are to be used as a baseline or as a 
reference to base further readings upon. 
 
Figure 45: Skin reflectance spectra of a male and female subject from Edwards & Dunkley 
1949. Note the relative homogeny and narrow wavelength variation (arrows) 217. 
 
It is important to understand that all objects and materials refract, and reflect 
light differently. In-fact the differences in any given objects spectoral 
reflectance allows us to perceive visual differences between objects 218. But 
why did all the reference spectra exhibit excessive specular highlights? An 
objects surface properties will influence the pattern of spectoral reflectance, 
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for example a glossy surface will reflect some or all of the light in a regular 
fashion i.e. will exhibit high levels of spectoral reflectance. On the other hand 
an object with a matt surface will scatter light in all directions and will not 
exhibit high levels of spectoral reflectance 218.  
Not only do an objects surface texture influence spectoral reflectance but also 
its shape. Highlights will “attach” themselves to areas of high curvature along 
the long axis of the curve 219. Thus a glossy, spherical object will by its very 
composition display a high level of reflectance, especially if it is in a brightly lit 
environment. If for example a glossy snooker ball is placed resting on top of 
the flat, matt felt of the snooker table under a bright light one can imagine the 
effect of spectoral reflectance. The snooker ball will be shiny with glinting 
edges (points of maximal curvature) whilst the matt felt of the table will display 
an even, soft texture with no glinting edges or reflections. Another factor 
influencing spectoral reflectance is movement of the object. Motion causes 
specular highlights to glide across the surface of the object (again imagine a 
snooker ball rolling across the snooker table) 220.  
If we extrapolate this understanding of what characteristics of any given 
objects cause it to produce large amounts of specular highlights we can 
hypothesise as to some of the reasons why the capture of reference spectra 
was not possible. Firstly, very bright studio-quality photographic lighting 
illuminated the clinical area where the spectoral measurements were taken. 
The tendency for any object to reflect in this bright light would likely increase. 
Secondly, whilst most skin is clearly matt, there are some reasons why trail 
subjects may have a more glossy sheen to their skin than one would expect, 
that would increase the spectoral reflectance. Many of the trail subjects will 
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have been applying moisturising cream to their scars as instructed by their 
surgeon and this will cause the skin to become glossier in appearance. Also 
anecdotally, depending on the length of time from surgery skin does tend to 
adapt a tighter, shiner appearance (although no reference to this could be 
found in the literature and it remains a clinical observation only).  
The appearance of some of the photographs show the glossy nature of the 
skin (Figure 46). It should be noted though in photographs that showed 
evidence of significant reflectance, typically the more lateral aspects of the 
scars (under the breast mound) appear more matt in nature whilst the medial 
aspect of the scars more shiny (Figure 46 & 47). It is suggested that this is 
partially due to the shadow effect of the breast above the central and lateral 
aspects of the scar.  
 
 
Figure 46: An example of a photograph unsuitable for analysis due to uneven illumination and 
highlights. Note the relative shade of the left side of the image compared to the right and the 
bright flash reflection in the centre of the scar.  
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Figure 47: A closer photograph of a trail participant’s right sub-mammary scar. Note the 
glossy sheen to the right of the black line (medial aspect) with strong reflectance of the studio 
lights and the relative lack of reflection on the left (lateral) side. 
 
 
Since spectoral measurements were taken on the medial aspects of the 
scars, under bright illumination this is likely this is the main reason why the 
returned images were unusable. Another aspect to consider is that the 
subjects chests are not flat, they are curved overlying the ribs. As has been 
discussed above spectoral reflectance will be increased on the curved edge of 
any object. Since the spectra were recorded from this curved area it is 
possible that this too contributed to excessive reflection. Similarly the fact that 
movement can increase an objects reflectance may also have contributed 
somewhat. The area under examination, on the chest wall, is constantly 
moving with respiratory effort and whilst the effect of this is likely to be small it 
may well have contributed to an overall effect of excessive reflectance. 
However it would of course be unreasonable to ask a trail subject to hold their 
breath when taking such readings due to the time involved. 
We must also consider the possibility of equipment or procedural failure when 
gathering data. However no equipment problems were identified during the 
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equipment use and the spectrometer and software were checked for error by 
a company technician before and after use so mechanical error would seem 
unlikely. Procedural error may also have contributed and cannot be ruled out. 
Such errors may include movement of the spectrometer when taking readings 
or taking readings at too vertical an angle (Figure 48), however specific 
procedural or handling errors during the sampling could not be identified.  
 
 
Figure 48: Holding the spectrometer probe too vertically will increase the amount of specular 
reflections (indicated by the black arrows) collected by the device 
 
 
In the absence of having baseline reference spectra from the subjects skin an 
alternative was sought. A previously collected spectral analysis of the skin 
was used in its place. The spectral library was gathered by a technician at 
ColourWorker®, John Anderson, who has Fitzpatrick type II skin for use in a 
previous (unpublished) referencing procedure performed by the company. 
The reference spectra were based on a library of progressively erythematous 
skin from the forearm. In total 10 spectra were obtained and spanned the skin 
tones from white, natural skin to reddened, erythematous skin (the erythema 
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was induced by vigorous rubbing). It was felt that this was a suitable and 
reliable alternative baseline that the software could use as a reference. 
Discussion of ColourWorker®  Scar Colour Analysis 
 
As can be seen from the results a total of 44 scar photographs were analysed 
for colour using ColourWorker®. Of these images, 35 were deemed to be 
unsuitable for analysis. The photographs were individually examined to 
assess suitability for analysis. Whilst there were not strictly defined criteria to 
determine usability, any photos that macroscopically showed evidence of 
moderate to severe specular highlights, or evidence of uneven illumination 
were rejected, following discussion with ColourWorker® technician John 
Anderson (Figures 49 & 50). The remaining 9 photographs were subsequently 
examined for colour using the software. 
 
 
Figure 49: A photograph rejected for analysis. The photo exhibits moderate evidence of 
highlights (centrally) and uneven shading. 
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Figure 50: Another photograph rejected for analysis. Note the excessive glossy highlights and 
marked difference in shading between the right and left sides of the image. 
 
 
Figure 51: A photograph that was selected for colour examination. Note the smooth, even 
lighting with no shadows or reflected light. 
 
The effect of analysing colour form photographs such as those in figures 49-
50 results in oddly shaped, un-representative scar evaluation curves (Figure 
52). No meaningful data can be retrieved from such curves.  
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Figure 52: Scar evaluation curves taken from the photograph in the top left of the figure. Note 
the glossy highlights on the raw image on the and its effect on the resulting curve. The curve 
shows a wandering ΔLab line with unusual peaks and troughs. 
 
If one compares the curve in Figure 52, taken from an image with excessive 
highlights, to one taken from one of the images deemed suitable for analysis 
one can see the difference in the resulting evaluation curve. The curve is well 
defined, smooth and documents the gradual change in colour from the red of 
the scar tissue to the normal skin tone on either side (Figure 53). From such a 
curve reliable Lab coordinates can be recorded relating to the skin and scar 
colour. 
 
Figure 53: The good quality photograph in the top left of this figure results in a smooth 
evaluation curve with no irregularities.  
 
From the 9 images from which colour analysis was performed the estimated 
scar width and the maximum colour difference (ΔLab) of scar versus skin are 
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indicated by the red and green lines respectively. The sample size was too 
small to perform any form of statistical analysis upon however the results do 
raise some points worthy of discussion.  
It would certainly appear from the 9 images selected for analysis that the 
ColourWorker® software is capable of accurately recording the colour of both 
scar and the surrounding skin, which could potentially form the basis of a scar 
colour assessment adjunct. The software was easily able to plot the maximal 
difference in Lab reading between the scars and surrounding skin and this in 
theory could be repeated over time to document the improvement of a scar in 
terms of maturity or in response to treatment. One would expect that as the 
scar improves in colour the evaluation curve would become flatter i.e. the scar 
evaluation integrals will decrease. This may well be useful for patients as well 
as clinicians so that they may see graphical evidence of improvement. In 
theory the technique is easily compatible with clinical work as all the analysis 
could be done from a digital photograph which many patients will be having 
taken anyway as part of their clinical documentation. Similarly the colour 
analysis and graphical output from the software takes minimal time and could 
easily be undertaken in a clinical environment by either clinically skilled staff 
or non-skilled workers who have been trained on the software. 
However the results gained during this trail do suggest that the technology 
and technique need refining and further experimental evaluation before this 
software could be used routinely. A major problem with the data gathered for 
this colour analysis from digital photos is that of the quality of the photos 
themselves. Only 9 out of 44 images (20.5%) were suitable for analysis owing 
to uneven shading and high light reflection within the pictures. This is not to 
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say that the photographs were of poor quality, or unclear, or not clinically 
useful for making visual assessments of the scar, rather that they exhibited 
qualities that made the gathering of quantitative colour information difficult. 
One can only assume this would be a problem that may be even more 
prominent in clinical areas without standardised lighting and equipment. An 
additional problem could be that many different people may take photos in a 
clinical setting and this would likely result in a further lack of standardisation 
and unusable images. A larger number of people involved in taking the 
images could also lead to unsuitable photographs being evaluated, resulting 
in erroneous clinical information being gathered. A particular problem would 
be the inclusion of photographs with moderate evidence of highlights that may 
be subtle to the untrained eye. Data taken from such an image would likely 
show a reduced height of the generated scar evaluation curve i.e. to the 
uninitiated looking at the data it may seem that the scar was improving in 
colour as its colour nearly matches that of the surrounding skin according to 
the evaluation curve. This of course would be erroneous data that would be 
obvious on simple clinical examination but often clinicians collecting treatment 
and service evaluation data will not be the same staff that has examined the 
patient so the possibility of clinical error would be high.  
It is possible that the amount of light reflection and uneven illumination could 
be partly improved through the use of a professional photographer, 
specialised lighting conditions, and the use of a polarizing lens filter which 
may improve this kind of colour analysis. However in most clinical practices 
this would not be feasible as access to medical photographers and 
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specialised equipment is limited and in any case would increase the amount 
of time required to assess patients to unacceptable levels.  
The other major problem we encountered using the ColourWorker® was due 
to the fact that the algorithm used by the software to interpret colour from 
selected photographs requires the use of reference spectra. As discussed 
earlier no usable reference spectra were gathered from this trail and in order 
to evaluate colour from the 9 selected trail photographs we utilised previously 
obtained reference spectra from a single subject. Whilst undoubtedly a useful 
solution in these particular circumstances the accurate measurement of colour 
from photographs depends on the acquirement of a representative reference 
spectra. It could be argued that the use of the reference spectra from a male 
forearm with Fitzpatrick type II skin is not representative of the sub-mammary 
skin of 9 women with variation in their skin tones. If the reference spectra 
used is not wholly representative then the software will not reliably or 
quantitatively interpret colour from the photos. It is impossible to estimate the 
effect that this may have had on our results and as such the Lab readings 
obtained need to be interpreted with caution. In the wider clinical context this 
too may cause potential problems as all clinics would have to have a bank of 
suitable reference spectra to use in order that the technology gives reliable 
results. 
Discussion of Eykona®  Results 
 
The Eykona® device was used successfully to image scars within this study. 
All 43 scars that were analysed by the device returned meaningful data. 
Average Lab colours of the areas of interest were easily and consistently 
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generated in a readily reproducible fashion. It would certainly appear that the 
methodology was sound to facilitate this area of the study.  
It can be seen that the colour differences within the 43 scar observed by the 
Eykona® device show good correlation with the Manchester Scar Scales 
grading system of slightly mismatched, obviously mismatched, and grossly 
mismatched scars. That is, the Lab values obtained across these Manchester 
grades fell into statistically different ranges (of colour) following Mann-Whitney 
U tests. It was found that statistically significant differences were observed 
between ΔLab values in the slightly and obviously mismatched groups 
(p<0.025) and between the obviously and grossly mismatched groups (p 
<0.05).  
There exists a problem however when looking at these results. It can be seen 
that the majority (79%) of the 43 scars were classified as “slightly 
mismatched” by the Manchester Score. Yet these scars exhibited the largest 
amount of standard deviation (ΔLab) upon quantitative analysis (Figures 32 & 
33). This suggests that subjective scar groupings, such as those used by the 
Manchester Scar Scale (and others), are inherently flawed. Such subjective 
groupings cannot objectively assess scar colour with any degree of 
confidence. This may be in part because although the observer may be 
physically able to distinguish between thousands of different colours the 
human brain is unable to reliably or accurately quantify the colour or its 
intensity 4. Diverse ranges of scar colours therefore are likely to be included 
within the same classification of such scales. Indeed if one applies 
quantitative analysis of the classification with a suitable device e.g. the 
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Eykona® a high degree of colour variability is likely to be seen. Indeed this is 
reflected very clearly in these results.  
Within the scars analysed in this trail sub-group very few were classified as 
“obviously” or “grossly” mismatched. Again, this is likely because these are 
relatively broad descriptive terms thus are interpreted differently between 
raters and present problems when trying to ascertain a true quantitative value. 
It is also not clear what (if any) clinical impact there is between a scar 
classified as “obviously” or “grossly” mismatched exists, especially if these 
groups themselves exhibit relatively wide standard deviations in terms of 
quantitative analysis. The number of scar classified as such in this study is too 
small to draw firm conclusions; only 3 scars were classified as “grossly 
mismatched”, and 6 as “obviously mismatched”. However there is such wide 
variation in the standard deviation (ΔLab), especially of the slightly 
mismatched group, that clearly some scars of equal quantitatively defined Lab 
colour have been placed in different Manchester Scar Scale categories by the 
same rater. One can only assume that this effect would be magnified if 
multiple raters were involved in scar assessment using subjective colour 
measurements.  
 No scars were classified as “perfect match” within this study group. It is not 
surprising that there were no “perfect match” scars observed, as by definition, 
if a scar matches the surrounding skin it is not visible and one must question if 
the injury being assessed was sufficient enough to induce a scarred wound. 
This is clearly not the case in surgical wounds such as those being assessed 
in this trail. One could argue that such a classification has no place in routine 
scar assessment system at all. Though of course if using the Manchester 
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scale (or others that incorporate a similar classification) to evaluate scar 
treatments then it may be useful to include in the unlikely event of a truly 
revolutionary scar treatment. 
The accurate evaluation of scar colour in a simple and quantitative manner 
that can be used within the clinical setting has long been a key challenge that 
has helped to drive the development of scar assessment systems. It would 
appear that the Eykona® device is a useful tool and is well suited to 
quantifying scar colour. The device has demonstrated reliability and 
consistency in gathering clinically useful data. Not only this but we have 
demonstrated that the quantitative data gathered by the device correlates well 
with the established Manchester Scar Assessment whilst also suggesting that 
such non-quantitative scales show a lack of resolution between visually very 
distinct scars. Partly the devices effectiveness in colour analysis may reside in 
the fact that unlike standard photography or some colorimetric devices the 
Eykona® records colour in a constant fashion that is totally independent of 
local or ambient lighting conditions. Similarly the angle the image is taken at 
also does not change the ability to record colour. These design factors make 
the device particularly suited to use within the clinical context where multiple 
users (often non-specialists) may be collecting data, and ambient lighting is 
typically varied and certainly not standardised in clinical areas. 
 These results suggest that scar colour assessment can be conducted in the 
routine clinical environment in a quantitative manner with ease. This allows for 
greater clinical accuracy that may alter clinical management, but possibly 
more importantly allows both patients and clinicians to visualise clinical 
improvement (or deterioration) with time to measure treatment effect. This 
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form of colour data collection also circumvents some of the problems that 
affect other devices on the market such as tri-stimulus colorimetric devices 
that can generally only analyse small areas of a scar but also have to be 
pressed against the skin, which may produce false colour readings due to a 
blanching effect.  
We suggest that devices such as the Eykona® and other similar products 
have an important role in future scar studies and will allow ordinary physicians 
and patients to assess scars in a more quantitative fashion that is currently 
available in the clinical environment.  
 
Colour Analysis Conclusions 
 
We have used two different methodologies during this study to attempt to 
more accurately record scar colour: the Eykona® 3D camera and the 
ColourWorker® system software. Colour data was obtained from the analysed 
scars with both devices however the Eykona® camera appears to be gather 
the most reliable colour data. The Eykona® gathered statistically significant 
data from all scars imaged, under standardised and reproducible conditions. 
Whereas the ColourWorker® system was unable to obtain reliable colour 
information from a large number of the digital photographs due to the 
presence of mostly unavoidable photographic artefacts such as reflected 
highlights and shading irregularities. This small sample number did not allow 
for robust analysis of the technique. Furthermore the gathering of the 
referencing spectra required to validate the colour analysis of the software 
was unsuccessful and as such an alternative was utilised rendering the 9 
 142 
analyses performed of uncertain colour accuracy. Further work is required to 
obtain reliable reference spectra and to increase the volume of photographic 
data collection that can be analysed to test any potential utility of this software 
in either the research or clinical environment.   
 Evaluation of scar colour forms an important part of many scar scales but 
frequently lacks standardisation or quantification. We have demonstrated that 
scar colour can be reliably calculated through the use of a 3D camera in a 
manner that would be compatible with clinical use and suggest that such 
devices would play an important part of future scar research but also are well 
suited to act as a clinical adjunct to routine scar evaluation. We suggest that 
devices such as this could potentially replace the subjective colour 
assessment element of traditional scar assessment scales with further 
research. The particular efficacy of this method of scar colour evaluation is 
that all aspects of the analysed image e.g. lighting and scale etc are 
standardised automatically by the device and image capture is quick and 
easily performed in the clinical environment. We hope to further investigate 
this potential in routine clinical practice. 
 
Future Directions 
 
Insulin and Scarring 
 
A total of 90 patients were recruited into this study and the remaining cohort of 
trial participants will continue to be followed-up and their scars assessed for a 
total of not less than a year. The participants will be asked to rate the quality 
 143 
of their scars by means of a questionnaire, specifically to elucidate personal 
perception of any difference between their scars. This data will then be 
analysed to determine any statistical significance existing between the treated 
and placebo scars.  
Photographs taken at the 1-year follow-up will also be reviewed by a panel of 
independent experts using an adapted version of the Manchester scale 
without the texture portion (giving a maximum score of 24). Once the scar 
assessment was completed, the data will be un-blinded and analysed to see if 
there is a statistical difference in the grades of scarring between the two 
treatments for all scars. At this point the data sets relating to the (already) 
conducted scar assessments at the 3 and 6-month visit for the entire cohort 
can also be unblended and analysed. The efficacy of insulin at all assessment 
points can then be determined. It remains to be seen if insulin has an overall 
effect on scarring at different points in time compared to placebo. It will be 
necessary to examine the link between the treatment effect noted in those 
affected by heavier scarring and in receipt of treatment A to see if any other 
associations exist, especially in relation to surgery type. 
It would also be desirable to further work upon a potential mechanism of 
action of insulin in the context of scar formation. The defining of a precise 
mechanism of action would potentially allow refining of any future marketable 
treatment for scarring and increase scientific knowledge in the area. Insights 
may possibly be gained into this though in vivo studies involving the tissue 
culture of fibroblasts and observing treatments effect of the addition of insulin. 
Further histological evaluation of treated scars from any future study would 
also be very useful to demonstrate any treatment effect at the cellular level 
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and allow quantification of any morphological and inflammatory differences 
between insulin and placebo treated scars.     
Eykona®  Device 
 
The ability to record quantitative scar colour with ease in the clinical 
environment has great potential. However as a stand-alone measure may fail 
to be utilised routinely as the clinician or researcher will still likely have to 
record other properties of the scars using pre-existing, non-quantitative 
measures or assessment scales. In future studies we would like to assess the 
ability of the device to measure other physical scar characteristics. Since the 
device is capable of producing a full 3D reconstruction of the scar, with scale 
references, meaning that the length, thickness, and even potentially volume in 
bulky keloid or hypertrophic scars could be calculated. We suggest the next 
experimental phase should involve testing these devices capabilities in a 
clinical context over a diverse array of scar types and compare recorded 
measurements against a score from a standard scar scale, such as the 
Manchester. The aim would be to produce a new scar assessment scale that 
is entirely based on quantitative data gathered from a single image capture 
and could replace existing subjective scales. 
ColourWorker®  Software 
 
Attempts will be made to build a library of reliable reference spectra for the 
software to use. These spectra need to be recorded from across a variety of 
skin tones i.e. Fitzpatrick types and from a variety of body areas. Further 
photographic techniques such as the use of polarizing lens filters and 
specialised lighting rigs should be tested to see if these can reduce the 
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amount of uneven illumination and highlights allowing larger volumes of 
images to be analysed in order to validate the software in the analysis of scar 
colour. 
Assess Further Means of Quantifying Scar Characteristics 
 
Attempts to further quantify scar assessment within the clinical context will be 
made. Firstly, the texture/firmness of the scars will be measured through the 
use of graded Semmes-Weinstein Monofilaments. These filaments comprise 
a range of fibres from light through to heavy, which reliably apply a maximum 
pressure value (in grams) at their tip when pressed against the skin. The force 
is constant as the filaments deform upon the application of pressure above 
their threshold ensuring that an even maximum pressure is generated 
regardless of the force used. Each scar will therefore be tested with 
graduating filaments until the 1st filament is selected that is capable of 
indenting the scar without itself deforming. The weight (in grams) of that 
filament will be recorded as a direct quantitative measurement of the scars 
pliability.  
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APPENDICIES  
 
Appendix 1: SOP – Randomisation/syringe preparation.  
1. Take randomisation pack from Clinical trial record file and record patient ID 
number in the randomisation log. 
 
2. Record patient ID number and the date on exterior of randomisation pack 
and on instruction envelope contained within.  
 
3. Fill out top four labels with details of operator name, date of use, batch 
number and expiry date of the insulin. 
 
4. Out of sight of the trial’s Surgical Research Fellow and the operating 
surgeon, open instruction envelope and make up two syringes (one of 
diluent only [placebo] and the other of diluted insulin) as below and label 
accordingly (right or left breast as per instructions) using the top two 
adhesive labels on the label sheet.  
 
5. Using a 1ml diabetic syringe draw up 1ml of diluent (Insulin diluting medium 
for NovoRapid [NovoNordisk]– as supplied by pharmacy) and attach the 
appropriate label (right or left breast - according to instruction envelope). 
This should be done first to produce the placebo before drawing up the 
insulin to avoid any chance of contamination with insulin. 
 
6. To make up the insulin syringe (containing 1ml of a 0.4 units/ml dilution of 
Insulatard):  
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i. Using a standard 2ml syringe, take up 0.2 ml of 100 units/ml Insulatard 
([NovoNordisk] - as supplied from pharmacy) and then take up 1.8ml of 
diluent from the diluent bottle into the same syringe and mix well. (20units in 
2ml) 
ii. Inject 0.3ml of this back into the diluent bottle (containing the remaining 
7.2ml of diluent) and mix thoroughly. (3units in 7.5ml = 0.4units in 1ml) 
iii. Using a second 1ml diabetic syringe draw up 1ml of this diluted 
Insulatard (now in the diluent bottle) and attach the appropriate label (right or 
left breast - according to instruction envelope). 
 
7. Syringes should be prepared preferably just before use, but in case of 
delay, must be stored refrigerated and used within 4hrs. 
 
8. Place completed labels in operation record and in patient notes. 
 
9. Replace instructions in instruction envelope, re-seal and return 
randomisation pack envelope along with remaining labels to the Surgical 
Research fellow (MJ Hallam).  
 
10. Discard used syringes and needles in sharps container as normal practice 
 
11. Place used vials of insulin and diluent in bag provided, mark as used and 
return to pharmacy. 
 
 
 
 148 
Appendix 2: SOP – Insulin/Placebo injection technique. 
 
 
1. Measure and mark with a surgical marker pen the medial 3cm of the 
surgical incisions following wound suturing. 
 
2. Take the pre-filled syringe containing either placebo or insulin as 
directed by the randomisation SOP. 
 
3. Inject the entire syringe content equally in the subcutaneous plane 
along both sides of the medial 3cm of the incision using a linear 
threading injection technique.   
 
4. Repeat step 3 for the contralateral breast. 
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Appendix 3: Manchester Scar Scale 
The Manchester scar score is derived through assessing and applying a score 
to the following scar parameters- 
 
(1) visual analogue scale (VAS) 
(2) colour 
(3) surface 
(4) contour 
(5) distortion 
(6) texture 
 
The visual analogue scale is anchored at excellent and poor at the extremes 
of a fixed length scale. The position chosen along the analogue scale will be 
given a score by measurement between 0 and 10 at a later stage. 
 
 
 
 
Color (compared to the surrounding skin) 
1 Perfect 
2 Slightly mismatched 
3 Obviously mismatched 
4 Gross mismatch 
Appearance of skin over the scarred area 
1 Matte 
2 Shiny 
Contour 
1 Flush with surrounding skin 
2 Slightly proud/indented 
3 Hypertrophic 
4 Keloid 
Distortion 
1 None 
2 Mild 
3 Moderate 
4 Severe  
Excellent Poor 
 150 
Texture  (Note this section will be removed for grading of scars from 
photographs) 
1 Normal 
2 Just palpable 
3 Firm 
4 Hard 
 
 
Total score for graded items = SUM (points for the 5 graded parameters) 
     Original scale Adapted for grading of 
Photographs 
Interpretation: 
• Minimum score:     5    4 
• Maximum score:     18    14 
Plus points from the analogue scale 
• Minimum score:     5    4 
• Maximum score:     28    24 
 
• The higher the score the more abnormal the scar. 
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Appendix 4: SOP – Photographic recording technique. 
 
1. Turn on Interfit studio light 10 minutes prior to photography and ensure 
is in same place as marked on floor. 
 
2. Set camera to manual (M) and check settings are F – 5.0, 1/60, and 
lens on automatic focus. 
 
3. Have patient lay on couch at 45 degrees with breasts lifted to expose 
medial end of scar (ensure the scar/skin is not pulled taut). 
 
4. Place photographic standardization card, marked with “right” or “left” 
(as appropriate) beneath the medial 3cm of the scar and bring the 
camera to a distance of approximately 15inches from lens to skin (so 
that the whole of the 5cm scale on the photographic standardization 
card nearly fills the width of the camera view). 
 
5. Take several shots of each breast scar, checking to ensure that you 
have a good focused and lit shot of each scar. 
 
6. Download the photographs immediately into a file containing the 
patients hospital number, initials, dob and date of visit. 
 
7. Backup onto external hard-drive and send images with hospital number 
and date of visit to Pharmecosse Ltd for back-up. 
 
8. Fill in CRF as appropriate. 
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Appendix 5: Preparation of Frozen Sections For Microscopy Procedure 
 
• Embed tissue in OCT embedding matrix and freeze in liquid nitrogen.  
Store at -30 0C. 
• Coat twin frosted glass slides (0.8-1.0mm) with Vectabond. 
• Place block of embedded tissue in cryostat (Bright Instruments) to 
reach temperature. 
• Attach block to chuck with OCT embedding matrix and leave until 
attached. 
• Cut 30µm sections until a cross section of the tissue is seen. 
• Cut sections at approximately 12µm and check under the microscope 
that the section is showing the area of tissue required. 
• Obtained sections ready for staining or storage at -80 0C until needed. 
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Appendix 6: Haemotoxylin & Eosin Histological Staining Procedure 
 
• Cut and air dry slides. 
• Filter haematoxylin. 
• Stain slides in haematoxylin for 30-60 seconds. 
• Rinse in running tap water for 5 minutes minimum and if required check 
staining density under microscope. 
• Stain in 0.1% aqueous eosin for 4-6 minutes. 
• Rinse in 70% IMS for 30 seconds 
• Rinse in 100% IMS for 2 minutes x 2. 
• Xylene for 2 minutes – agitate. 
• Xylene for 4 minutes or until ready to mount. 
• Mount in DPX. 
• Air dry overnight. 
• Store at room temperature. 
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Appendix 7: Picosirius Red Histological Staining Procedure 
 
• Bring frozen sections to room temperature. 
• Fix sections 1 hour in 4% paraformaldehyde. 
• Wash off in tap water 
• Wash in phosphate buffered saline. 
• Immerse in Picosirius Red stain (neat) 1 hour 
• Wash 2x acidified water. 
• Dehydrate – 30sec 70% alcohol, 2 x 2 min 100% alcohol, 1 x 2 min 
xylene, 1 x 4 min xylene. 
• Mount in xylene. 
 
Product Information: 
Sirius Red (Direct Red 80) Sigma Aldrich 365548 or 43665 0.5g 
Sat. aq. Solution picric Acid 
(1.3% in water, Sigma Aldrich P6744-1GA)     
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Appendix 8: Alpha-Smooth Muscle Antibody Immunohistochemistry 
Staining Procedure 
• Allow sections to dry and come to room temperature. 
• Fix sections- 10 min neat acetone 4 0C for α-sma antibody. 
• Wash 3 x 3 min in phosphate buffered saline. 
• Block 30 minutes in 2.5% appropriate serum at room temperature. 
Block in serum the 20 antibody raised in. 
• Blot off excess serum. 
• Incubate in 10 antibody 1 hour room temperature or overnight at 40C in 
humid chamber, dilute antibody in 1% bovine serum albumin in PBS. 
• Wash 3 x 3 min in PBS. 
• Incubate in 20 antibody 30 min room temperature in the dark, dilute 20 
antibody in 1% BSA in PBS. 
• Wash 3 x 3 min in PBS. 
• Wash 1 x 3 min in deionised water. 
• Wipe off excess water from the slide. 
• Mount in Vectashield with DAPI with coverslip. 
 
Product Information: 
Primary antibody - Monoclonal anti actin α-sm Clone 1A4.  Purified mouse 
Ig. (Sigma A 5228) used at dilution 1:200 
Secondary antibody-Green secondary horse anti mouse IgG Dylight 488 
(Abcam DI 2488) used at dilution 1:200. 
Bovine serum albumin fraction V Roche 10735 09400-1 
Serum -Horse serum 2.5% Vecta labs S-2012 
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Appendix 9: Raw RBG signals of scars and adjacent skin with 
conversion to Lab values using an ICC colour profile developed by 
Eykona®  
 
 
	  
	  	   Lab	  conversion	  for	  RGB	  values	   	  	  
	  
	  	  
	   	   	   	   	   	  
	  	  
	  
L	   a	   b	  
	   	   	   	  
	  	  
	  
	  	  
	   	   	   	   	   	  
DELTA	  
Mean	  colour	  R:203.5	  G:117.8	  B:107.5	   59.6	   41.5	   8.6	   Scar	  vs	  skin	  Rt	   4.3	   -­‐4.5	   2.9	   6.9	  
Mean	  colour	  R:218	  G:136.6	  B:121.7	   63.5	   35.6	   11.5	   Scar	  vs	  skin	  Lt	   9.5	   -­‐11.5	   4.2	   15.5	  
Mean	  colour	  R:224	  G:138.7	  B:124.6	   63.9	   36.9	   11.5	  
	   	   	   	  
	  	  
Mean	  colour	  R:181.1	  G:97.5	  B:89.8	   54.1	   47.2	   7.3	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:106	  G:79.4	  B:61.3	   47.9	   20.0	   23.7	   Scar	  vs	  skin	   3.1	   0.1	   4.9	   5.8	  
Mean	  colour	  R:96	  G:72.6	  B:58.7	   44.7	   19.9	   18.8	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:164.2	  G:131.2	  B:109.6	   61.4	   21.5	   9.4	   Scar	  vs	  skin	  Lt	   -­‐6.8	   1.8	   -­‐4.9	   8.6	  
Mean	  colour	  R:178.9	  G:148	  B:124	   64.5	   17.3	   10.4	   Scar	  vs	  skin	  Rt	   -­‐6.1	   8.1	   -­‐5.0	   11.3	  
Mean	  colour	  R:197.3	  G:167.6	  B:137	   67.6	   13.5	   14.3	  
	   	   	   	  
	  	  
Mean	  colour	  R:218.6	  G:187.4	  B:151.4	   71.3	   15.5	   15.2	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:207.8	  G:187	  B:147.8	   70.9	   10.2	   16.9	   Scar	  vs	  skin	  Lt	   -­‐5.0	   6.4	   -­‐6.6	   10.5	  
Mean	  colour	  R:180.6	  G:151.1	  B:127.7	   64.9	   16.4	   9.3	   Scar	  vs	  skin	  Rt	   5.3	   -­‐2.8	   3.9	   7.1	  
Mean	  colour	  R:203.5	  G:182.6	  B:145.4	   69.9	   10.0	   16.0	  
	   	   	   	  
	  	  
Mean	  colour	  R:178.5	  G:155.4	  B:126.4	   65.6	   12.9	   13.0	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:211.4	  G:189.3	  B:151.9	   71.3	   11.4	   15.0	   Scar	  vs	  skin	  Lt	   7.6	   -­‐9.9	   2.0	   12.7	  
Mean	  colour	  R:169.8	  G:133.7	  B:109.9	   62.3	   21.9	   11.6	  
	   	   	   	  
	  	  
Mean	  colour	  R:180.2	  G:140.5	  B:115.6	   63.7	   21.4	   13.0	   Scar	  vs	  skin	  Rt	   -­‐7.6	   9.8	   -­‐2.5	   12.6	  
Mean	  colour	  R:207.2	  G:182.1	  B:147.6	   69.9	   12.2	   14.1	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:168.4	  G:137.4	  B:112.1	   62.8	   19.3	   12.0	   Scar	  vs	  skin	  Lt	   2.1	   -­‐5.5	   3.0	   6.6	  
Mean	  colour	  R:178.5	  G:153.9	  B:122	   65.6	   13.3	   16.1	  
	   	   	   	  
	  	  
Mean	  colour	  R:172.9	  G:140.9	  B:114.5	   63.5	   18.8	   13.1	   Scar	  vs	  skin	  Rt	   -­‐1.5	   3.7	   -­‐3.3	   5.2	  
Mean	  colour	  R:171.7	  G:145.4	  B:115.3	   64.3	   15.6	   15.3	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:161.2	  G:119	  B:102.6	   59.0	   27.3	   7.4	   Scar	  vs	  skin	   -­‐7.0	   10.8	   -­‐6.2	   14.3	  
Mean	  colour	  R:190.7	  G:156.5	  B:128.8	   66.0	   16.5	   13.5	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:113.9	  G:84.8	  B:71.5	   49.2	   23.8	   12.2	   Scar	  vs	  skin	   -­‐8.6	   6.8	   -­‐1.2	   11.0	  
Mean	  colour	  R:137.7	  G:116.6	  B:92.7	   57.8	   17.0	   13.4	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:166.2	  G:130	  B:107.1	   61.5	   22.6	   11.2	   Scar	  vs	  skin	   -­‐3.5	   6.8	   -­‐4.7	   9.0	  
Mean	  colour	  R:177.6	  G:148.6	  B:118.1	   64.9	   15.8	   15.9	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:206.8	  G:181.7	  B:151.5	   69.6	   12.9	   10.1	   Scar	  vs	  skin	   11.7	   -­‐16.2	   2.9	   20.2	  
Mean	  colour	  R:158.9	  G:114.4	  B:99	   57.9	   29.1	   7.3	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:144.7	  G:128.4	  B:98.4	   60.6	   13.6	   16.4	   Scar	  vs	  skin	   1.3	   -­‐2.5	   3.7	   4.7	  
Mean	  colour	  R:142.8	  G:123.2	  B:98.2	   59.3	   16.2	   12.7	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:202.6	  G:181.9	  B:148.2	   69.6	   10.5	   12.8	   Scar	  vs	  skin	   4.6	   -­‐7.7	   3.2	   9.5	  
Mean	  colour	  R:186.7	  G:151.4	  B:128.6	   65.1	   18.2	   9.6	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:198.8	  G:163.2	  B:136.2	   67.0	   16.2	   12.7	   Scar	  vs	  skin	   8.0	   -­‐12.7	   6.1	   16.2	  
 157 
Mean	  colour	  R:164.7	  G:118.7	  B:103.6	   59.0	   28.9	   6.6	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:171.4	  G:138.4	  B:118.1	   62.8	   20.4	   8.0	   Scar	  vs	  skin	   1.7	   -­‐6.5	   1.9	   7.0	  
Mean	  colour	  R:174.2	  G:128.8	  B:113.2	   61.1	   26.9	   6.1	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:149.8	  G:119.2	  B:99.3	   58.7	   22.4	   9.4	   Scar	  vs	  skin	   -­‐9.4	   12.1	   -­‐2.7	   15.5	  
Mean	  colour	  R:193.7	  G:173.1	  B:142.2	   68.2	   10.4	   12.1	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:206.6	  G:171.2	  B:133.2	   68.6	   14.5	   21.4	   Scar	  vs	  skin	   4.2	   -­‐7.2	   8.7	   12.1	  
Mean	  colour	  R:188	  G:144.6	  B:120.5	   64.4	   21.7	   12.7	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:120.3	  G:91.7	  B:79.2	   51.0	   24.2	   7.4	   Scar	  vs	  skin	   -­‐16.3	   11.2	   -­‐2.8	   19.9	  
Mean	  colour	  R:194.2	  G:167.6	  B:140.9	   67.3	   13.0	   10.3	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:96.9	  G:67.1	  B:52.4	   43.0	   24.3	   25.1	   Scar	  vs	  skin	   4.3	   -­‐3.2	   3.7	   6.5	  
Mean	  colour	  R:86.7	  G:57.5	  B:47.2	   38.7	   27.5	   21.4	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:164.1	  G:134.4	  B:105.2	   62.5	   18.7	   15.9	   Scar	  vs	  skin	   -­‐3.9	   5.8	   -­‐5.4	   8.8	  
Mean	  colour	  R:184.3	  G:157	  B:119.6	   66.4	   12.9	   21.4	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:182	  G:142.8	  B:121	   63.8	   21.1	   10.0	   Scar	  vs	  skin	   -­‐5.3	   6.9	   -­‐8.8	   12.4	  
Mean	  colour	  R:208.2	  G:175.1	  B:138.5	   69.2	   14.2	   18.9	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:212.3	  G:175.5	  B:131.2	   69.8	   14.7	   26.7	   Scar	  vs	  skin	  Rt	   2.0	   -­‐3.6	   6.3	   7.6	  
Mean	  colour	  R:209.3	  G:164.3	  B:130.6	   67.8	   18.2	   20.3	  
	   	   	   	  
	  	  
Mean	  colour	  R:186.4	  G:156.3	  B:120.5	   66.3	   14.1	   20.4	   Scar	  vs	  skin	  Lt	   4.8	   -­‐7.1	   4.1	   9.5	  
Mean	  colour	  R:163.1	  G:128.7	  B:100.8	   61.5	   21.3	   16.3	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:136.4	  G:97.3	  B:88	   52.1	   30.8	   2.7	   Scar	  vs	  skin	   3.7	   -­‐3.3	   -­‐3.5	   6.1	  
Mean	  colour	  R:127.5	  G:83.8	  B:76.3	   48.4	   34.1	   6.2	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:230.7	  G:168.5	  B:143.3	   69.0	   27.7	   14.5	   Scar	  vs	  skin	   9.3	   -­‐8.0	   3.8	   12.9	  
Mean	  colour	  R:185.6	  G:117.8	  B:102.2	   59.7	   35.8	   10.7	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:212.7	  G:137.6	  B:124.9	   63.6	   33.6	   8.3	   Scar	  vs	  skin	  Rt	   9.9	   -­‐6.4	   10.6	   15.8	  
Mean	  colour	  R:237.6	  G:176	  B:148.1	   70.6	   29.9	   15.2	  
	   	   	   	  
	  	  
Mean	  colour	  R:195	  G:124	  B:115.2	   60.7	   36.2	   4.5	   Scar	  vs	  skin	  Lt	   -­‐6.3	   7.7	   -­‐3.8	   10.7	  
Mean	  colour	  R:231.2	  G:177.1	  B:150.7	   70.0	   25.9	   12.1	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:230.5	  G:165.3	  B:145.3	   68.0	   29.0	   10.7	   Scar	  vs	  skin	  Rt	   8.7	   -­‐11.0	   3.4	   14.5	  
Mean	  colour	  R:196.3	  G:116.8	  B:106.8	   59.3	   40.1	   7.2	  
	   	   	   	  
	  	  
Mean	  colour	  R:212.4	  G:121	  B:112	   60.2	   42.2	   8.2	   Scar	  vs	  skin	  Lt	   -­‐6.8	   9.9	   -­‐3.5	   12.5	  
Mean	  colour	  R:231	  G:156.9	  B:138.9	   67.0	   32.3	   11.8	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:197.7	  G:169.5	  B:133.1	   68.0	   12.1	   19.1	   Scar	  vs	  skin	   2.9	   -­‐5.0	   7.2	   9.2	  
Mean	  colour	  R:184.3	  G:151.5	  B:125.7	   65.1	   17.1	   11.9	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:152.5	  G:123.5	  B:95.3	   60.3	   19.9	   17.2	   Scar	  vs	  skin	   -­‐5.9	   5.3	   -­‐6.2	   10.1	  
Mean	  colour	  R:184.8	  G:153.6	  B:114.9	   66.2	   14.5	   23.4	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:179.5	  G:159.1	  B:120.8	   66.5	   10.2	   20.9	   Scar	  vs	  skin	  Lt	   8.2	   -­‐14.9	   6.6	   18.3	  
Mean	  colour	  R:214.4	  G:187.8	  B:145.6	   71.5	   12.3	   20.5	   Scar	  vs	  skin	  Rt	   5.6	   -­‐3.9	   -­‐0.1	   6.8	  
Mean	  colour	  R:187.9	  G:153.2	  B:118.2	   66.0	   16.2	   20.6	  
	  
58.3	   25.1	   14.2	   	  	  
Mean	  colour	  R:152.3	  G:114.8	  B:92.3	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:218.8	  G:181.9	  B:136.7	   71.1	   15.7	   26.2	   Scar	  vs	  skin	   9.0	   -­‐5.1	   9.1	   13.8	  
Mean	  colour	  R:165.7	  G:131.1	  B:102	   62.1	   20.8	   17.1	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:205.1	  G:173.1	  B:134	   68.9	   13.3	   21.5	   Scar	  vs	  skin	   5.3	   -­‐11.0	   9.6	   15.5	  
Mean	  colour	  R:185.3	  G:138.5	  B:116.1	   63.5	   24.2	   12.0	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:209.9	  G:175.2	  B:134.1	   69.4	   14.2	   23.4	   Scar	  vs	  skin	   3.8	   -­‐4.5	   8.3	   10.2	  
Mean	  colour	  R:193.1	  G:152.5	  B:124.8	   65.7	   18.7	   15.0	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:253.5	  G:237.3	  B:197.2	   83.5	   16.8	   22.2	   Scar	  vs	  skin	   13.3	   -­‐6.8	   11.3	   18.7	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Mean	  colour	  R:228.2	  G:180.4	  B:153.3	   70.2	   23.5	   10.9	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:213.3	  G:181.4	  B:136.9	   70.7	   13.4	   24.8	   Scar	  vs	  skin	   5.7	   -­‐7.8	   7.7	   12.3	  
Mean	  colour	  R:191.1	  G:146.1	  B:117.5	   65.0	   21.2	   17.1	   	  	   	  	   	  	   	  	   	  	  
Mean	  colour	  R:254.5	  G:243.4	  B:208	   85.7	   14.8	   21.0	   Scar	  vs	  skin	   14.1	   -­‐7.3	   11.4	   19.5	  
Mean	  colour	  R:229.8	  G:189.3	  B:160.3	   71.6	   22.1	   9.7	   	  	   	  	   	  	   	  	   	  	  
	  
	  	  
	   	   	  
delta	  L	   delta	  a	   delta	  b	   	  	  
	  
	  	  
	   	  
MEAN	   7.549155591	   7.59366375	   5.369025818	   	  	  
	  
	  	  
	   	   	   	   	  
Min	   4.7	  
	  
	  	  
	   	   	   	   	  
Mean	   11.6	  
	  
	  	  
	   	   	   	   	  
Max	   20.2	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Appendix 10: Example of Scar Assessment Score Sheets Presented to 
the Expert Panel (scaled to fit) 
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Appendix 11: Permission to Use Figures Produced By John Anderson 
Of ColourWorker®   
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